US7838216B1
(en)
|
1986-03-05 |
2010-11-23 |
The United States Of America, As Represented By The Department Of Health And Human Services |
Human gene related to but distinct from EGF receptor gene
|
US6121424A
(en)
*
|
1991-11-25 |
2000-09-19 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5869620A
(en)
*
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US20050058638A1
(en)
*
|
1987-05-21 |
2005-03-17 |
Huston James S. |
Biosynthetic binding proteins for immuno-targeting
|
WO1990005144A1
(en)
*
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
|
WO1992015682A1
(en)
*
|
1991-02-27 |
1992-09-17 |
Creative Biomolecules, Inc. |
Serine-rich peptide linkers
|
KR100334695B1
(ko)
*
|
1991-08-05 |
2002-04-27 |
리차아드제이마세이 |
표적화된 촉매 단백질에 의해 활성화되는 선구 약제
|
DE69334255D1
(de)
*
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
US20070031931A1
(en)
*
|
1992-02-06 |
2007-02-08 |
Chiron Corporation |
Biosynthetic binding proteins for immuno-targeting
|
US7754211B2
(en)
*
|
1992-04-10 |
2010-07-13 |
Research Development Foundation |
Immunotoxins directed against c-erbB-2(HER-2/neu) related surface antigens
|
US20080152586A1
(en)
*
|
1992-09-25 |
2008-06-26 |
Avipep Pty Limited |
High avidity polyvalent and polyspecific reagents
|
AU5670194A
(en)
*
|
1992-11-20 |
1994-06-22 |
Enzon, Inc. |
Linker for linked fusion polypeptides
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
US5837242A
(en)
*
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
AU680685B2
(en)
|
1993-09-22 |
1997-08-07 |
Medical Research Council |
Retargeting antibodies
|
US5753225A
(en)
*
|
1993-12-03 |
1998-05-19 |
The Regents Of The University Of California |
Antibodies that mimic actions of neurotrophins
|
IT1264083B1
(it)
*
|
1993-12-10 |
1996-09-10 |
Enea Ente Nuove Tec |
Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia.
|
US5763733A
(en)
*
|
1994-10-13 |
1998-06-09 |
Enzon, Inc. |
Antigen-binding fusion proteins
|
US6514942B1
(en)
*
|
1995-03-14 |
2003-02-04 |
The Board Of Regents, The University Of Texas System |
Methods and compositions for stimulating T-lymphocytes
|
AUPO591797A0
(en)
*
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US6267958B1
(en)
*
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US5968511A
(en)
*
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
CN1214044C
(zh)
*
|
1996-03-27 |
2005-08-10 |
基因技术股份有限公司 |
ErbB3抗体
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
IL127558A0
(en)
*
|
1996-07-03 |
1999-10-28 |
Genentech Inc |
Hepatocyte growth factor receptor agonists and uses thereof
|
DE69731836T2
(de)
*
|
1996-07-23 |
2005-12-01 |
Pangenetics B.V. |
Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
|
CA2262001C
(en)
*
|
1996-08-05 |
2003-05-20 |
President And Fellows Of Harvard College |
Mhc binding peptide oligomers and methods of use
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
ATE444760T1
(de)
*
|
1997-01-13 |
2009-10-15 |
Univ Emory |
Glutathion zur behandlung von influenzainfektionen
|
WO1998033809A1
(en)
*
|
1997-01-31 |
1998-08-06 |
The General Hospital Corporation |
Compositions and methods for imaging gene expression
|
US20030109680A1
(en)
*
|
2001-11-21 |
2003-06-12 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US5986065A
(en)
*
|
1997-03-10 |
1999-11-16 |
Sunol Molecular Corporation |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US7749498B2
(en)
*
|
1997-03-10 |
2010-07-06 |
Genentech, Inc. |
Antibodies for inhibiting blood coagulation and methods of use thereof
|
US20060235209A9
(en)
*
|
1997-03-10 |
2006-10-19 |
Jin-An Jiao |
Use of anti-tissue factor antibodies for treating thromboses
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
US6323322B1
(en)
|
1997-04-30 |
2001-11-27 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
PT998486E
(pt)
|
1997-06-13 |
2007-08-21 |
Genentech Inc |
''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
FR2766826B1
(fr)
*
|
1997-08-04 |
2001-05-18 |
Pasteur Institut |
Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
|
US6737249B1
(en)
*
|
1997-08-22 |
2004-05-18 |
Genentech, Inc. |
Agonist antibodies
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
DE19819846B4
(de)
*
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
WO1999061057A2
(en)
*
|
1998-05-23 |
1999-12-02 |
Tanox, Inc. |
Molecules targeting cd40 and tumor cells
|
GB9812545D0
(en)
*
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
US7387772B1
(en)
*
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US7833528B2
(en)
*
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
US7074405B1
(en)
*
|
1998-06-22 |
2006-07-11 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
US6962702B2
(en)
*
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
DE19831429A1
(de)
*
|
1998-07-07 |
2000-04-27 |
Jerini Biotools Gmbh |
Verfahren zur Identifizierung und chemisch-synthetischen Nachahmung von Bindungsstellen auf Proteinen
|
US6228360B1
(en)
*
|
1998-08-19 |
2001-05-08 |
Ajinomoto Co., Inc. |
Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
|
US7067144B2
(en)
*
|
1998-10-20 |
2006-06-27 |
Omeros Corporation |
Compositions and methods for systemic inhibition of cartilage degradation
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
US7118743B2
(en)
|
1998-11-17 |
2006-10-10 |
Tanox, Inc. |
Bispecific molecules cross-linking ITIM and ITAM for therapy
|
AU1727500A
(en)
*
|
1998-11-17 |
2000-06-05 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
JP4579471B2
(ja)
*
|
1999-06-25 |
2010-11-10 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる前立腺癌の処置
|
DK2283866T3
(en)
|
1999-06-25 |
2015-05-18 |
Genentech Inc |
METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
EP2112167A3
(en)
|
1999-06-25 |
2010-12-22 |
Genentech, Inc. |
Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
ATE438411T1
(de)
*
|
1999-08-27 |
2009-08-15 |
Genentech Inc |
Dosierung für die behandlung mit anti erbb2- antikörpern
|
EP2289549A3
(en)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
US6794494B1
(en)
*
|
2003-04-14 |
2004-09-21 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
BR0108001A
(pt)
*
|
2000-02-01 |
2004-01-06 |
Tanox Inc |
Moléculas ativadoras de apc com ligação para cd-40
|
CA2400622A1
(en)
*
|
2000-02-24 |
2001-08-30 |
Eidgenossische Technische Hochschule Zurich |
Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
|
US6319694B1
(en)
*
|
2000-03-03 |
2001-11-20 |
Genopsys, Inc. |
Random truncation and amplification of nucleic acid
|
US7097840B2
(en)
*
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
AU5720601A
(en)
*
|
2000-04-26 |
2001-11-07 |
Elusys Therapeutics Inc |
Bispecific molecules and uses thereof
|
WO2001083781A2
(en)
*
|
2000-04-28 |
2001-11-08 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
ATE441433T1
(de)
*
|
2000-05-19 |
2009-09-15 |
Genentech Inc |
Gennachweisverfahren zur verbesserung der wahrscheinlichkeit einer wirkungsvollen antwort auf eine krebstherapie mit einem erbb- antagonisten
|
WO2001091793A1
(en)
*
|
2000-05-26 |
2001-12-06 |
Smithkline Beecham Corporation |
Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
|
EP2052742A1
(en)
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
GB0027328D0
(en)
*
|
2000-06-23 |
2000-12-27 |
Aventis Pharma Inc |
Bioengineered vehicles for targeted nucleic acid delivery
|
RU2280254C2
(ru)
*
|
2000-09-07 |
2006-07-20 |
Шеринг Акциенгезельшафт |
РЕЦЕПТОР EDb-ДОМЕНА ФИБРОНЕКТИНА
|
US20020086814A1
(en)
*
|
2000-11-15 |
2002-07-04 |
Brian Storrie |
B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging
|
WO2002053596A2
(en)
|
2001-01-05 |
2002-07-11 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
CN1247258C
(zh)
|
2001-04-24 |
2006-03-29 |
默克专利有限公司 |
使用抗血管生成剂和TNFα的联合疗法
|
CN1195779C
(zh)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
抗人卵巢癌抗人cd3双特异性抗体
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
ES2372321T3
(es)
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
BR0306715A
(pt)
*
|
2002-01-03 |
2004-12-28 |
Schering Ag |
Métodos para diagnóstico e tratamento de tumores
|
JP4460302B2
(ja)
|
2002-02-05 |
2010-05-12 |
ジェネンテック インコーポレイテッド |
タンパク質精製法
|
US6869787B2
(en)
*
|
2002-02-27 |
2005-03-22 |
The United States Of America As Represented By The Secretary Of The Army |
Ricin vaccine and methods of making and using thereof
|
SI2289942T1
(sl)
|
2002-04-10 |
2013-11-29 |
Genentech, Inc. |
Variante protitelesa proti HER2
|
US20030228606A1
(en)
*
|
2002-04-11 |
2003-12-11 |
Amgen Inc., A Corporation Of The State Of Delaware |
Her-2 receptor tyrosine kinase molecules and uses thereof
|
EP2011886A3
(en)
|
2002-04-16 |
2009-02-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
UA77303C2
(en)
*
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
CA2490659C
(en)
*
|
2002-06-28 |
2014-08-19 |
Syed V. S. Kashmiri |
Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
|
MXPA05000403A
(es)
|
2002-07-15 |
2005-07-22 |
Genentech Inc |
Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
|
AU2003265994B2
(en)
|
2002-09-11 |
2010-04-01 |
Genentech, Inc. |
Protein purification
|
AU2002951853A0
(en)
*
|
2002-10-04 |
2002-10-24 |
Commonwealth Scientific And Industrial Research Organisation |
Crystal structure of erbb2 and uses thereof
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
AU2003295798B2
(en)
*
|
2002-11-21 |
2009-09-10 |
Genentech, Inc. |
Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
|
US20040186160A1
(en)
*
|
2002-12-13 |
2004-09-23 |
Sugen, Inc. |
Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
|
PT1585743E
(pt)
*
|
2002-12-19 |
2007-07-12 |
Pfizer |
Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas.
|
JP4764334B2
(ja)
|
2003-02-01 |
2011-08-31 |
タノックス インコーポレーテッド |
高親和性抗ヒトIgE抗体
|
CN103265477B
(zh)
|
2003-02-26 |
2017-01-11 |
苏根公司 |
作为蛋白激酶抑制剂的氨基杂芳基化合物
|
KR20050119671A
(ko)
*
|
2003-04-03 |
2005-12-21 |
화이자 인코포레이티드 |
Ag013736을 포함하는 제형
|
ZA200507757B
(en)
|
2003-04-04 |
2007-01-31 |
Genentech Inc |
High concentration antibody and protein formulations
|
WO2004091657A2
(en)
|
2003-04-09 |
2004-10-28 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
|
US7425328B2
(en)
*
|
2003-04-22 |
2008-09-16 |
Purdue Pharma L.P. |
Tissue factor antibodies and uses thereof
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
KR20060006975A
(ko)
|
2003-05-30 |
2006-01-20 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
PT1631313E
(pt)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
ES2527102T3
(es)
*
|
2003-06-19 |
2015-01-20 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de trastornos relacionados con la coagulación
|
NZ544317A
(en)
|
2003-07-08 |
2009-05-31 |
Genentech Inc |
IL-17 A/F heterologous polypeptides and therapeutic uses thereof
|
WO2005016968A2
(en)
|
2003-07-28 |
2005-02-24 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
HN2004000285A
(es)
*
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
EP1660503A1
(en)
*
|
2003-08-29 |
2006-05-31 |
Pfizer Inc. |
Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
|
ES2314444T3
(es)
*
|
2003-08-29 |
2009-03-16 |
Pfizer Inc. |
Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
|
US7589181B2
(en)
*
|
2003-08-29 |
2009-09-15 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
ES2472690T3
(es)
|
2003-11-17 |
2014-07-02 |
Genentech, Inc. |
Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
|
US7671072B2
(en)
*
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
EP2168986A3
(en)
|
2004-02-19 |
2010-07-28 |
Genentech, Inc. |
CDR-repaired antibodies
|
WO2005094830A1
(en)
*
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
AU2005249490B2
(en)
|
2004-06-01 |
2010-07-29 |
Genentech, Inc. |
Antibody drug conjugates and methods
|
AU2005249566B2
(en)
|
2004-06-04 |
2010-11-11 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
SV2006002143A
(es)
|
2004-06-16 |
2006-01-26 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del cancer resistente al platino
|
EP2322215A3
(en)
*
|
2004-07-16 |
2011-09-28 |
Pfizer Products Inc. |
Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
|
ATE456579T1
(de)
|
2004-07-20 |
2010-02-15 |
Genentech Inc |
Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
SI1784396T1
(sl)
*
|
2004-08-26 |
2011-03-31 |
Pfizer |
S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
|
MX2007001986A
(es)
*
|
2004-08-26 |
2007-05-10 |
Pfizer |
Compuestos de aminoheteroarilo como inhibidores de proteina quinasa.
|
ES2341351T3
(es)
*
|
2004-08-26 |
2010-06-18 |
Pfizer, Inc. |
Compuestos de aminoheteroarilo enantiomericamente puros como inhibidores de proteina cinasas.
|
WO2006034335A2
(en)
*
|
2004-09-21 |
2006-03-30 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Method of detecting cancer based on immune reaction to boris
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
PL1791565T3
(pl)
|
2004-09-23 |
2016-10-31 |
|
Modyfikowane cysteiną przeciwciała i koniugaty
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20060107555A1
(en)
*
|
2004-11-09 |
2006-05-25 |
Curtis Marc D |
Universal snow plow adapter
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
CN101141981A
(zh)
|
2005-01-21 |
2008-03-12 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
RU2007133660A
(ru)
*
|
2005-02-09 |
2009-03-20 |
Дженентек, Инк. (Us) |
Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
|
DK1853718T3
(en)
|
2005-02-15 |
2015-11-09 |
Univ Duke |
ANTI-CD19 ANTIBODIES AND THEIR USE IN ONCOLOGY
|
EP2399605A1
(en)
*
|
2005-02-23 |
2011-12-28 |
Genentech, Inc. |
Extending time to disease progression or survival in cancer patients
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
CA2603093A1
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
AU2006238930B2
(en)
|
2005-04-26 |
2010-12-23 |
Pfizer Inc. |
P-cadherin antibodies
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
EP3498289A1
(en)
|
2005-07-07 |
2019-06-19 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
JP2009504183A
(ja)
|
2005-08-15 |
2009-02-05 |
ジェネンテック・インコーポレーテッド |
遺伝子破壊、それに関連する組成物および方法
|
PT2447283E
(pt)
|
2005-09-07 |
2015-10-08 |
Pfizer |
Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1)
|
EP1926996B1
(en)
|
2005-09-20 |
2011-11-09 |
OSI Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
KR20150055628A
(ko)
|
2005-11-04 |
2015-05-21 |
제넨테크, 인크. |
안질환 치료를 위한 보체 경로 억제제의 용도
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
WO2007081608A2
(en)
|
2005-11-21 |
2007-07-19 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007126439A2
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
EP1973948B1
(en)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
US7625759B2
(en)
|
2005-12-19 |
2009-12-01 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
SI1973950T1
(sl)
|
2006-01-05 |
2015-01-30 |
Genentech, Inc. |
Anti-EphB4 protitelesa in postopki njihove uporabe
|
EP2287196A3
(en)
*
|
2006-01-13 |
2011-05-04 |
Irm Llc |
Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
|
US20090130098A1
(en)
|
2006-01-18 |
2009-05-21 |
Merck Patent Gmbh |
Specific therapy using integrin ligands for treating cancer
|
US20080311107A1
(en)
|
2006-02-17 |
2008-12-18 |
Genetech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP1996716B1
(en)
|
2006-03-20 |
2011-05-11 |
The Regents of the University of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
EP2389951A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
WO2007126455A2
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
UA91129C2
(ru)
|
2006-05-09 |
2010-06-25 |
Пфайзер Продактс Инк. |
Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
|
NL2000613C2
(nl)
|
2006-05-11 |
2007-11-20 |
Pfizer Prod Inc |
Triazoolpyrazinederivaten.
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
BRPI0712222B1
(pt)
|
2006-06-02 |
2021-10-13 |
Aveo Pharmaceuticals, Inc. |
Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
|
KR101196184B1
(ko)
|
2006-06-02 |
2012-11-01 |
아베오 파마슈티컬즈, 인크. |
간세포 성장 인자 (hgf) 결합 단백질
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
DK2426150T3
(en)
|
2006-06-30 |
2018-01-22 |
Novo Nordisk As |
ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
US7862813B2
(en)
|
2006-07-29 |
2011-01-04 |
Bjork Jr Robert Lamar |
Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
|
EP2520935A3
(en)
|
2006-08-09 |
2013-02-13 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
WO2008031056A2
(en)
|
2006-09-08 |
2008-03-13 |
Medimmune, Llc |
Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2008031051A2
(en)
|
2006-09-08 |
2008-03-13 |
United Therapeutics Corporation |
Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
WO2008061019A2
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
EP2727936B1
(en)
|
2006-11-22 |
2016-09-07 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
CA2670696A1
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
JP5386364B2
(ja)
|
2006-12-18 |
2014-01-15 |
ジェネンテック, インコーポレイテッド |
抗Notch3アンタゴニスト抗体とNotch3関連疾患の予防及び治療におけるその使用
|
WO2008079302A2
(en)
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
EP2094303A1
(en)
*
|
2006-12-22 |
2009-09-02 |
Novelix Therapeutics Gmbh |
Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
|
ES2399159T3
(es)
|
2007-01-18 |
2013-03-26 |
Merck Patent Gmbh |
Terapia y medicamento específicos usando ligandos de integrinas para el tratamiento del cáncer
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
ES2379413T3
(es)
|
2007-02-22 |
2012-04-25 |
Genentech, Inc. |
Procedimientos para detectar la enfermedad inflamatoria del intestino
|
WO2008109440A2
(en)
|
2007-03-02 |
2008-09-12 |
Genentech, Inc. |
Predicting response to a her dimerisation inhibitor based on low her3 expression
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
CN101861168B
(zh)
|
2007-05-07 |
2014-07-02 |
米迪缪尼有限公司 |
抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
|
US20090163698A1
(en)
*
|
2007-05-11 |
2009-06-25 |
John Joseph Grigsby |
Method for Preparing Antibody Conjugates
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
LT3327026T
(lt)
|
2007-07-09 |
2019-11-11 |
Genentech Inc |
Disulfidinio ryšio redukcijos prevencija rekombinantinių polipeptidų gaminimo metu
|
JP2010533495A
(ja)
|
2007-07-16 |
2010-10-28 |
ジェネンテック, インコーポレイテッド |
ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用
|
PT2176296E
(pt)
|
2007-07-16 |
2012-05-14 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
WO2009028158A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
|
EP2195425A4
(en)
|
2007-08-24 |
2011-01-19 |
Oncotherapy Science Inc |
PKIB AND NAALADL2 FOR TARGET GENES OF THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
KR20100075857A
(ko)
|
2007-08-24 |
2010-07-05 |
온코세라피 사이언스 가부시키가이샤 |
폐암의 치료 및 진단의 표적유전자인 ebi3,dlx5,nptx1 및 cdkn
|
UA117446C2
(uk)
|
2007-08-29 |
2018-08-10 |
Санофі-Авентіс |
Гуманізоване антитіло до cxcr5
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
PT2185574E
(pt)
|
2007-09-07 |
2013-08-26 |
Agensys Inc |
Anticorpos e moléculas relacionadas que se ligam a proteínas 24p4c12
|
AR068563A1
(es)
|
2007-09-26 |
2009-11-18 |
Chugai Pharmaceutical Co Ltd |
Region constante de anticuerpo mutante
|
EP2207805B1
(en)
|
2007-10-02 |
2014-07-09 |
Genentech, Inc. |
Nlrr-1 antagonists and uses thereof
|
EP2050764A1
(en)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
ES2565202T3
(es)
|
2007-10-16 |
2016-04-01 |
Zymogenetics, Inc. |
Combinación de activador transmembrana y modulador de calcio e interactor de ligando de ciclofilina (TACI) y agentes anti-CD20 para tratamiento de enfermedades autoinmunitarias
|
ES2666170T3
(es)
|
2007-10-30 |
2018-05-03 |
Genentech, Inc. |
Purificación de anticuerpos mediante cromatografía de intercambio catiónico
|
MX2010005108A
(es)
|
2007-11-07 |
2010-05-27 |
Genentech Inc |
Composiciones y metodos para el tratamiento de trastornos microbianos.
|
WO2009064805A1
(en)
|
2007-11-12 |
2009-05-22 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of influenza
|
CA2706729A1
(en)
|
2007-11-29 |
2009-06-11 |
Genentech, Inc. |
Gene expression markers for inflammatory bowel disease
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
EP2769993A1
(en)
|
2007-12-14 |
2014-08-27 |
Novo Nordisk A/S |
Antibodies against human NKG2D and uses thereof
|
CA2711843C
(en)
|
2007-12-20 |
2018-11-13 |
Laboratory Corporation Of America Holdings |
Her-2 diagnostic methods
|
US8253725B2
(en)
*
|
2007-12-28 |
2012-08-28 |
St. Jude Medical, Atrial Fibrillation Division, Inc. |
Method and system for generating surface models of geometric structures
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
CA2712220A1
(en)
|
2008-01-24 |
2009-07-30 |
Novo Nordisk A/S |
Humanized anti-human nkg2a monoclonal antibody
|
US8420620B2
(en)
*
|
2008-01-24 |
2013-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Induced internalization of surface receptors
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MY157403A
(en)
|
2008-01-31 |
2016-06-15 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
EP2247615B1
(en)
|
2008-02-14 |
2014-07-30 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins that bind egfr
|
NZ600339A
(en)
|
2008-02-25 |
2013-12-20 |
Nestec Sa |
Drug selection for breast cancer therapy using antibody-based arrays
|
WO2009114560A2
(en)
|
2008-03-10 |
2009-09-17 |
Spaltudaq Corporation |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
ES2545977T3
(es)
|
2008-03-18 |
2015-09-17 |
Genentech, Inc. |
Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso
|
ES2354661B1
(es)
|
2008-05-08 |
2012-02-01 |
Consejo Superior De Investigaciones Científicas (Csic) |
Método para generar anticuerpos monoclonales que reconocen antígenos de membrana de células progenitoras neurales, anticuerpos producidos por dicho método, y usos.
|
US8093018B2
(en)
|
2008-05-20 |
2012-01-10 |
Otsuka Pharmaceutical Co., Ltd. |
Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
|
AR071874A1
(es)
|
2008-05-22 |
2010-07-21 |
Bristol Myers Squibb Co |
Proteinas de dominio de armazon basadas en fibronectina multivalentes
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
EP2318832B1
(en)
|
2008-07-15 |
2013-10-09 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
WO2010011349A2
(en)
*
|
2008-07-25 |
2010-01-28 |
Supergen, Inc. |
Pyrimidine-2,4-diamine jak2 kinase inhibiting anti-inflammation use
|
LT2848625T
(lt)
|
2008-08-14 |
2019-10-10 |
Genentech, Inc. |
Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
|
US8163497B2
(en)
|
2008-09-07 |
2012-04-24 |
Glyconex Inc. |
Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
US8476410B2
(en)
|
2008-10-16 |
2013-07-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
AU2009308293B2
(en)
|
2008-10-22 |
2015-02-05 |
Genentech, Inc. |
Modulation of axon degeneration
|
US8734795B2
(en)
|
2008-10-31 |
2014-05-27 |
Biogen Idec Ma Inc. |
Light targeting molecules and uses thereof
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
AU2009313902B9
(en)
|
2008-11-13 |
2014-03-27 |
The General Hospital Corporation |
Methods and compositions for regulating iron homeostasis by modulation of BMP-6
|
JP5677972B2
(ja)
*
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
JP6041489B2
(ja)
|
2008-11-22 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
乳癌の治療のための化学療法と併用した抗vegf抗体の使用
|
WO2010062857A1
(en)
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
WO2010065568A2
(en)
|
2008-12-01 |
2010-06-10 |
Laboratory Corporation Of America Holdings |
METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
US20100190963A1
(en)
|
2008-12-16 |
2010-07-29 |
Millipore Corporation |
Stirred Tank Reactor And Method
|
CN102256993A
(zh)
|
2008-12-16 |
2011-11-23 |
米利波尔公司 |
蛋白的纯化
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
AU2010204583A1
(en)
|
2009-01-15 |
2011-08-25 |
Laboratory Corporation Of America Holdings |
Methods of determining patient response by measurement of Her-3
|
JP2012517426A
(ja)
|
2009-02-09 |
2012-08-02 |
アステックス ファーマシューティカルズ インコーポレイテッド |
ピロロピリミジニルaxlキナーゼ阻害剤
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
US8679492B2
(en)
|
2009-02-23 |
2014-03-25 |
Glenmark Pharmaceuticals S.A. |
Humanized antibodies that bind to CD19 and their uses
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20120077696A1
(en)
|
2009-03-15 |
2012-03-29 |
Technion Research And Development Foundation Ltd. |
Soluble hla complexes for use in disease diagnosis
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
KR20130080871A
(ko)
|
2009-03-20 |
2013-07-15 |
제넨테크, 인크. |
이중특이적 항-her 항체
|
CN104788564A
(zh)
|
2009-03-25 |
2015-07-22 |
健泰科生物技术公司 |
抗-fgfr3抗体及其使用方法
|
JP6132548B2
(ja)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
抗FcRH5抗体および免疫接合体および使用方法
|
AU2010232692C1
(en)
|
2009-04-01 |
2017-06-01 |
Genentech, Inc. |
Treatment of insulin-resistant disorders
|
JP5616428B2
(ja)
|
2009-04-07 |
2014-10-29 |
ロシュ グリクアート アクチェンゲゼルシャフト |
三価の二重特異性抗体
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US8753631B2
(en)
*
|
2009-05-01 |
2014-06-17 |
New York University |
Therapeutic agents for inducing platelet fragmentation and treating thromboembolic disorders
|
JP5813630B2
(ja)
|
2009-05-14 |
2015-11-17 |
ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード |
微量ヒト血漿タンパク質バイオマーカーの新規なパネルを使用した肝線維症の臨床診断
|
US8858948B2
(en)
|
2009-05-20 |
2014-10-14 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
SG176103A1
(en)
|
2009-05-25 |
2011-12-29 |
Merck Patent Gmbh |
Continuous administration of cilengitide in cancer treatments
|
CN102421448A
(zh)
|
2009-05-29 |
2012-04-18 |
霍夫曼-拉罗奇有限公司 |
Her2信号传导调控剂在表达her2的胃癌患者中
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US20110002931A1
(en)
|
2009-06-23 |
2011-01-06 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
MX2012000417A
(es)
|
2009-07-07 |
2012-02-08 |
Genentech Inc |
Diagnostico y tratamiento de enfermedades desmielinizantes autoinmunitarias.
|
JP5795311B2
(ja)
|
2009-07-15 |
2015-10-14 |
ネステク ソシエテ アノニム |
抗体ベースのアレイを使用する胃癌療法のための薬物選択
|
AU2010276392A1
(en)
|
2009-07-20 |
2012-03-08 |
Genentech, Inc. |
Gene expression markers for Crohn's disease
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
EP2459184A1
(en)
|
2009-07-31 |
2012-06-06 |
The Brigham and Women's Hospital, Inc. |
Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
EP3431588A1
(en)
|
2009-08-11 |
2019-01-23 |
F. Hoffmann-La Roche AG |
Production of proteins in glutamine-free cell culture media
|
WO2011019679A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Ccr2 inhibitors for treating conditions of the eye
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
RU2576027C2
(ru)
|
2009-08-15 |
2016-02-27 |
Дженентек, Инк. |
Антиангиогенная терапия для лечения ранее подвергавшегося лечению рака молочной железы
|
WO2011028753A1
(en)
|
2009-09-01 |
2011-03-10 |
Genentech, Inc. |
Enhanced protein purification through a modified protein a elution
|
US20120157471A1
(en)
|
2009-09-01 |
2012-06-21 |
Pfizer Inc. |
Benzimidazole derivatives
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
AU2010310746B2
(en)
|
2009-10-20 |
2015-07-23 |
Nestec S.A. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
AR078716A1
(es)
|
2009-10-22 |
2011-11-30 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
JP2013508401A
(ja)
|
2009-10-22 |
2013-03-07 |
ジェネンテック, インコーポレイテッド |
軸索変性の調節
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
SI2496601T1
(sl)
|
2009-11-05 |
2017-09-29 |
F. Hoffmann-La Roche Ag |
Tehnike in sestavek za sekrecijo heterolognih polipeptidov
|
EP3002297B1
(en)
|
2009-11-30 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
MX354143B
(es)
|
2009-12-02 |
2018-02-14 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
|
AR078377A1
(es)
|
2009-12-11 |
2011-11-02 |
Genentech Inc |
Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
|
MY159156A
(en)
|
2009-12-21 |
2016-12-15 |
Genentech Inc |
Antibody formulation
|
EP2516465B1
(en)
|
2009-12-23 |
2016-05-18 |
F.Hoffmann-La Roche Ag |
Anti-bv8 antibodies and uses thereof
|
EP2519542B1
(en)
|
2009-12-28 |
2018-10-10 |
OncoTherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
KR102108226B1
(ko)
|
2010-02-12 |
2020-05-08 |
화이자 인코포레이티드 |
8-플루오로-2-{4-[(메틸아미노)메틸]페닐}-1,3,4,5-테트라하이드로-6h-아제피노[5,4,3-cd]인돌-6-온의 염 및 다형체
|
SI2536748T1
(sl)
|
2010-02-18 |
2014-12-31 |
Genentech, Inc. |
Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
|
CN103237810A
(zh)
|
2010-02-23 |
2013-08-07 |
霍夫曼-拉罗奇有限公司 |
用于治疗卵巢癌的抗血管发生疗法
|
WO2011106222A2
(en)
*
|
2010-02-23 |
2011-09-01 |
Corning Incorporated |
Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
AU2011223655A1
(en)
|
2010-03-03 |
2012-06-28 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
CA2783656A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011116396A2
(en)
|
2010-03-19 |
2011-09-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
|
EP2550295A1
(en)
|
2010-03-24 |
2013-01-30 |
F. Hoffmann-La Roche AG |
Anti-lrp6 antibodies
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
RU2636461C2
(ru)
|
2010-05-03 |
2017-11-23 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
AU2011250970B2
(en)
|
2010-05-10 |
2016-12-15 |
Sinica, Academia |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
WO2011146394A1
(en)
|
2010-05-17 |
2011-11-24 |
Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
CN102905718A
(zh)
|
2010-05-25 |
2013-01-30 |
弗·哈夫曼-拉罗切有限公司 |
纯化多肽的方法
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
WO2011150241A2
(en)
|
2010-05-28 |
2011-12-01 |
Genentech, Inc. |
Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
SG185430A1
(en)
|
2010-06-03 |
2012-12-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
MX336540B
(es)
|
2010-06-08 |
2016-01-22 |
Genentech Inc |
Conjugados y anticuerpos manipulados geneticamente con cisteina.
|
CN104689314B
(zh)
|
2010-06-16 |
2018-02-02 |
高等教育联邦系统-匹兹堡大学 |
内质蛋白的抗体及其用途
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
CN103153328A
(zh)
|
2010-07-16 |
2013-06-12 |
默克专利股份有限公司 |
肽在乳腺癌和/或骨转移灶的治疗中的用途
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
EP2596026B1
(en)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
US8900590B2
(en)
|
2010-08-12 |
2014-12-02 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
BR112013003361B8
(pt)
|
2010-08-13 |
2022-01-25 |
Roche Glycart Ag |
Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
|
TW201209063A
(en)
|
2010-08-13 |
2012-03-01 |
Roche Glycart Ag |
Anti-tenascin-C A2 antibodies and methods of use
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CA2805054A1
(en)
|
2010-08-25 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Antibodies against il-18r1 and uses thereof
|
CA3109036C
(en)
|
2010-08-31 |
2023-08-01 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
US20120089541A1
(en)
|
2010-08-31 |
2012-04-12 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
WO2012028683A1
(en)
|
2010-09-02 |
2012-03-08 |
Novartis Ag |
Antibody gel system for sustained drug delivery
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
JP6121904B2
(ja)
|
2010-09-08 |
2017-04-26 |
ハロザイム インコーポレイテッド |
条件的活性治療用タンパク質を評価および同定する、または発展させる方法
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
WO2012052948A1
(en)
|
2010-10-20 |
2012-04-26 |
Pfizer Inc. |
Pyridine- 2- derivatives as smoothened receptor modulators
|
TW201307385A
(zh)
|
2010-10-25 |
2013-02-16 |
Genentech Inc |
胃腸炎症和銀屑病以及哮喘的治療
|
SG190682A1
(en)
|
2010-11-10 |
2013-07-31 |
Genentech Inc |
Methods and compositions for neural disease immunotherapy
|
EP2643353A1
(en)
|
2010-11-24 |
2013-10-02 |
Novartis AG |
Multispecific molecules
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
WO2012075333A2
(en)
|
2010-12-02 |
2012-06-07 |
Prometheus Laboratories Inc. |
Her2delta16 peptides
|
US20120156194A1
(en)
|
2010-12-16 |
2012-06-21 |
Genentech, Inc. |
Diagnosis and treatments relating to th2 inhibition
|
UA115641C2
(uk)
|
2010-12-20 |
2017-11-27 |
Дженентек, Інк. |
Виділене антитіло, яке зв'язує мезотелін, та імунокон'югат, що його містить
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
SG191230A1
(en)
|
2010-12-23 |
2013-07-31 |
Nestec Sa |
Drug selection for malignant cancer therapy using antibody-based arrays
|
JP6162044B2
(ja)
|
2010-12-23 |
2017-07-12 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
結合剤
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
ES2656969T3
(es)
|
2010-12-23 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Detección de un dímero polipeptídico por un agente de unión bivalente
|
CA2817928C
(en)
|
2010-12-23 |
2019-10-01 |
Michael Gerg |
Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
JP2014511147A
(ja)
|
2011-02-10 |
2014-05-12 |
ロシュ グリクアート アーゲー |
改善された免疫療法
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
KR20140012098A
(ko)
|
2011-02-14 |
2014-01-29 |
테라클론 사이언시스, 아이엔씨. |
인플루엔자의 치료 및 진단을 위한 조성물 및 방법
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
RU2607038C2
(ru)
|
2011-02-28 |
2017-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Антигенсвязывающие белки
|
MX342034B
(es)
|
2011-02-28 |
2016-09-12 |
Hoffmann La Roche |
Proteinas monovalentes que se unen a antigenos.
|
WO2012116453A1
(en)
|
2011-03-03 |
2012-09-07 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
WO2012122499A2
(en)
|
2011-03-09 |
2012-09-13 |
Pestell Richard G |
Prostate cancer cell lines, gene signatures and uses thereof
|
SG193402A1
(en)
|
2011-03-15 |
2013-10-30 |
Theraclone Sciences Inc |
Compositions and methods for the therapy and diagnosis of influenza
|
EP3235508B1
(en)
|
2011-03-16 |
2020-12-30 |
Sanofi |
Compositions comprising a dual v region antibody-like protein
|
EP3590965A1
(en)
|
2011-03-29 |
2020-01-08 |
Roche Glycart AG |
Antibody fc variants
|
CA2831732C
(en)
|
2011-03-31 |
2019-12-31 |
Genentech, Inc. |
Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders
|
BR112013024717A2
(pt)
|
2011-04-07 |
2017-08-08 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, imunoconjugado, formulação farmacêutica, método de tratar um indivíduo que tem câncer e método de inibir proliferação celular em um indivíduo
|
WO2012142164A1
(en)
|
2011-04-12 |
2012-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
|
EP3536708A1
(en)
|
2011-04-19 |
2019-09-11 |
Pfizer Inc |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
CA2828662A1
(en)
|
2011-04-20 |
2012-10-26 |
Roche Glycart Ag |
Method and constructs for the ph dependent passage of the blood-brain-barrier
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
CA2833212C
(en)
|
2011-05-12 |
2020-06-09 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
|
MY175338A
(en)
|
2011-05-16 |
2020-06-19 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
AR086924A1
(es)
|
2011-06-15 |
2014-01-29 |
Hoffmann La Roche |
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
|
CA2835242A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CN107915775B
(zh)
|
2011-07-11 |
2022-07-12 |
伊克诺斯科学公司 |
结合ox40的抗体及其用途
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
MX2014001736A
(es)
|
2011-08-17 |
2014-03-31 |
Genentech Inc |
Inhibicion de angiogenesis en tumores refractarios.
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
EP2748202B1
(en)
|
2011-08-23 |
2018-07-04 |
Roche Glycart AG |
Bispecific antigen binding molecules
|
US9309306B2
(en)
|
2011-08-23 |
2016-04-12 |
Roche Glycart Ag |
Anti-MCSP antibodies
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
LT2748201T
(lt)
|
2011-08-23 |
2018-02-26 |
Roche Glycart Ag |
Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
|
MX356947B
(es)
|
2011-08-23 |
2018-06-20 |
Roche Glycart Ag |
Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
WO2013033623A1
(en)
|
2011-09-02 |
2013-03-07 |
Nestec S.A. |
Profiling of signal pathway proteins to determine therapeutic efficacy
|
GB201212550D0
(en)
|
2012-07-13 |
2012-08-29 |
Novartis Ag |
B cell assay
|
CA2846083A1
(en)
|
2011-09-15 |
2013-03-21 |
Genentech, Inc. |
Methods of promoting differentiation
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
WO2013043715A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
KR20140059246A
(ko)
|
2011-09-22 |
2014-05-15 |
화이자 인코포레이티드 |
피롤로피리미딘 및 퓨린 유도체
|
US9783613B2
(en)
|
2011-10-04 |
2017-10-10 |
Igem Therapeutics Limited |
IgE anti-HMW-MAA antibody
|
SG11201401287SA
(en)
|
2011-10-05 |
2014-05-29 |
Genentech Inc |
Methods of treating liver conditions using notch2 antagonists
|
ES2687951T3
(es)
|
2011-10-14 |
2018-10-30 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-HtrA1 y procedimientos de uso
|
WO2013056148A2
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
TW201325613A
(zh)
|
2011-10-28 |
2013-07-01 |
Genentech Inc |
治療黑色素瘤之治療組合及方法
|
CA2854330A1
(en)
|
2011-11-02 |
2013-05-10 |
Genentech, Inc. |
Overload and elute chromatography
|
KR20140076602A
(ko)
|
2011-11-08 |
2014-06-20 |
화이자 인코포레이티드 |
항-m-csf 항체를 사용한 염증성 장애의 치료 방법
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
SG11201402619VA
(en)
|
2011-11-23 |
2014-10-30 |
Igenica Biotherapeutics Inc |
Anti-cd98 antibodies and methods of use thereof
|
BR112014012882A2
(pt)
|
2011-11-29 |
2017-06-13 |
Genentech Inc |
método, anticorpo, polinucleotídeo, célula hospedeira, linhagem celular de hibridoma, uso do anticorpo e kit
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
US9963511B2
(en)
|
2011-12-22 |
2018-05-08 |
Hoffmann-La Roche Inc. |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
EP2794651B1
(en)
|
2011-12-22 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
EP2794635B8
(en)
|
2011-12-22 |
2018-11-14 |
H. Hoffnabb-La Roche Ag |
Ion exchange membrane chromatography
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
EP3663314A1
(en)
|
2012-01-09 |
2020-06-10 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
WO2013109856A2
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
SG10201601747XA
(en)
|
2012-01-18 |
2016-04-28 |
Genentech Inc |
Anti-LRP5 Antibodies And Methods Of Use
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
JP6545959B2
(ja)
|
2012-02-11 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
Rスポンジン転位およびその使用方法
|
ES2676031T3
(es)
|
2012-02-15 |
2018-07-16 |
F. Hoffmann-La Roche Ag |
Cromatografía de afinidad basada en el receptor Fc
|
RU2014138586A
(ru)
|
2012-03-02 |
2016-04-20 |
Рош Гликарт Аг |
Прогностический биомаркер для лечения рака антителами с повышенной антителозависимой клеточной цитотоксичностью
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
BR112014024017A8
(pt)
|
2012-03-27 |
2017-07-25 |
Genentech Inc |
Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
CN104470544B
(zh)
|
2012-05-01 |
2018-01-12 |
基因泰克公司 |
抗pmel17抗体和免疫缀合物
|
CA2872540A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
AU2013262977A1
(en)
|
2012-05-14 |
2015-01-22 |
Prostagene, Llc |
Using modulators of CCR5 for treating cancer
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
WO2013183032A2
(en)
|
2012-06-08 |
2013-12-12 |
Glenmark Pharmaceuticals S.A. |
Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof
|
TW201410706A
(zh)
|
2012-06-15 |
2014-03-16 |
Genentech Inc |
抗-pcsk9抗體、調配物、劑量及使用方法
|
ES2597228T3
(es)
|
2012-06-27 |
2017-01-17 |
F. Hoffmann-La Roche Ag |
Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
CA2871386A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
HUE029435T2
(en)
|
2012-07-04 |
2017-02-28 |
Hoffmann La Roche |
Anti-theophylline antibodies and methods of their application
|
WO2014006124A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Covalently linked antigen-antibody conjugates
|
CA3188124A1
(en)
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
SG11201500087VA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
AR091700A1
(es)
|
2012-07-09 |
2015-02-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd79b
|
CA2874904A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
EP2869847B1
(en)
|
2012-07-09 |
2017-12-06 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
AU2013289881B2
(en)
|
2012-07-13 |
2018-01-18 |
Zymeworks Bc Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2014009465A1
(en)
|
2012-07-13 |
2014-01-16 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
MX365382B
(es)
|
2012-08-07 |
2019-05-31 |
Roche Glycart Ag |
Una combinación de inmunoconjugado y anticuerpo para usarse en el tratamiento de cáncer.
|
MA20150232A1
(fr)
|
2012-08-08 |
2015-07-31 |
Roche Glycart Ag |
Protéines de fusion de l'interleukine-10 et leurs utilisations
|
CN109705218B
(zh)
|
2012-08-09 |
2022-07-19 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
WO2014036520A1
(en)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
BR112015003938A2
(pt)
|
2012-09-14 |
2018-09-04 |
Hoffmann La Roche |
métodos de produção de polipeptídeos, de produção de aglutinantes multiespecíficos, de seleção de aglutinantes multiespecíficos, de seleção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação farmcêutica e uso de anticorpo biespecífico
|
RU2015112024A
(ru)
|
2012-10-05 |
2016-11-27 |
Дженентек, Инк. |
Способы диагностики и лечения воспалительного заболевания кишечника
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
AU2013329311A1
(en)
|
2012-10-09 |
2015-04-30 |
Igenica Biotherapeutics, Inc. |
Anti-C16orf54 antibodies and methods of use thereof
|
US9394257B2
(en)
|
2012-10-16 |
2016-07-19 |
Tolero Pharmaceuticals, Inc. |
PKM2 modulators and methods for their use
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
SG11201502538TA
(en)
|
2012-11-08 |
2015-05-28 |
Hoffmann La Roche |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
CA2890669A1
(en)
|
2012-11-13 |
2014-05-22 |
Genetech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
MX2015006149A
(es)
|
2012-11-15 |
2015-08-05 |
Genentech Inc |
Cromatografia de intercambio ionico de gradiente de ph mediada por concentracion ionica.
|
CN104813168B
(zh)
|
2012-11-30 |
2017-10-20 |
霍夫曼-拉罗奇有限公司 |
需要pd‑l1抑制剂综合疗法的患者的鉴定
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
TR201815254T4
(tr)
|
2013-01-02 |
2018-11-21 |
Glenmark Pharmaceuticals Sa |
Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
|
WO2014113729A2
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Mecicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
DK2961771T3
(da)
|
2013-02-26 |
2020-03-02 |
Roche Glycart Ag |
Bispecifikke, T-celle-aktiverende, antigenbindende molekyler, der er specifikke for CD3 og CEA
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
BR112015021423A2
(pt)
|
2013-03-06 |
2017-07-18 |
Genentech Inc |
métodos de tratamento de câncer, de células de câncer e de câncer resistente a antagonista de egfr, métodos de aumento da sensibilidade e da eficácia de tratamento de câncer e métodos de atraso, de tratamento de indivíduos com câncer e de extensão
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
RU2707550C2
(ru)
|
2013-03-13 |
2019-11-27 |
Дженентек, Инк. |
Составы со сниженным окислением
|
AR095396A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones de anticuerpo
|
LT2968466T
(lt)
|
2013-03-13 |
2018-10-10 |
F. Hoffmann-La Roche Ag |
Sumažintos oksidacijos kompozicijos
|
RU2015139054A
(ru)
|
2013-03-14 |
2017-04-19 |
Дженентек, Инк. |
Способы лечения рака и профилактики лекарственной резистентности рака
|
AU2014239903A1
(en)
|
2013-03-14 |
2015-09-17 |
Genentech, Inc. |
Combinations of a MEK inhibitor compound with an HER3/EGFR inhibitor compound and methods of use
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
BR112015022019A2
(pt)
|
2013-03-14 |
2017-08-29 |
Genentech Inc |
Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
|
WO2014144865A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
KR20150130451A
(ko)
|
2013-03-15 |
2015-11-23 |
제넨테크, 인크. |
암 치료 방법 및 항암제 내성 예방을 위한 방법
|
CN105143258B
(zh)
|
2013-03-15 |
2020-06-23 |
Ac免疫有限公司 |
抗Tau抗体和使用方法
|
SG11201507367PA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Cell culture compositions with antioxidants and methods for polypeptide production
|
SG10201706210WA
(en)
|
2013-03-15 |
2017-09-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
MY176706A
(en)
|
2013-03-15 |
2020-08-19 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
MD20180107A2
(ro)
|
2013-03-18 |
2019-06-30 |
Biocerox Products B.V. |
Anticorpi anti-CD134 (OX40) umanizaţi şi utilizarea acestora
|
SG11201507974RA
(en)
|
2013-03-27 |
2015-10-29 |
Genentech Inc |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
EP2983710B1
(en)
|
2013-04-09 |
2019-07-31 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
CA2908743A1
(en)
|
2013-05-20 |
2014-11-27 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
KR20160013163A
(ko)
|
2013-05-24 |
2016-02-03 |
네스텍 소시에테아노님 |
과민성 대장 증후군 진단을 예측하기 위한 경로 특이적 검정법
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
WO2015006507A1
(en)
|
2013-07-09 |
2015-01-15 |
Annexon, Inc. |
Methods of treatment for alzheimer's disease and huntington's disease
|
KR102251127B1
(ko)
|
2013-07-12 |
2021-05-11 |
제넨테크, 인크. |
이온 교환 크로마토그래피 입력 최적화의 설명
|
AU2014290044B2
(en)
*
|
2013-07-17 |
2020-10-29 |
Foundation Medicine, Inc. |
Methods of treating urothelial carcinomas
|
EP3022221B1
(en)
|
2013-07-18 |
2021-09-15 |
Taurus Biosciences, LLC |
Humanized antibodies with ultralong complementarity determining regions
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
CN105848746B
(zh)
|
2013-09-05 |
2019-07-09 |
豪夫迈·罗氏有限公司 |
用于层析重复利用的方法
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
SG11201601770YA
(en)
|
2013-09-12 |
2016-04-28 |
Halozyme Inc |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
JP6546178B2
(ja)
|
2013-09-13 |
2019-07-17 |
ジェネンテック, インコーポレイテッド |
細胞株中の宿主細胞タンパク質及び組換えポリペプチド産物を検出及び定量化するための組成物並びに方法
|
NZ756750A
(en)
|
2013-09-13 |
2022-05-27 |
Genentech Inc |
Methods and compositions comprising purified recombinant polypeptides
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
SI3049441T1
(sl)
|
2013-09-27 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Formulacije protiteles proti PD-L1
|
WO2015044083A1
(en)
|
2013-09-27 |
2015-04-02 |
F. Hoffmann-La Roche Ag |
Thermus thermophilus slyd fkbp domain specific antibodies
|
US20150104392A1
(en)
|
2013-10-04 |
2015-04-16 |
Aptose Biosciences Inc. |
Compositions, biomarkers and their use in the treatment of cancer
|
RU2016117978A
(ru)
|
2013-10-11 |
2017-11-17 |
Дженентек, Инк. |
Ингибиторы nsp4 и способы их применения
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
US20150147333A1
(en)
|
2013-10-18 |
2015-05-28 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
JP6715767B2
(ja)
|
2013-10-23 |
2020-07-01 |
ジェネンテック, インコーポレイテッド |
好酸球性疾患の診断及び治療方法
|
EP3068892A4
(en)
|
2013-11-13 |
2017-05-31 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
|
SI3071597T1
(sl)
|
2013-11-21 |
2020-11-30 |
F. Hoffmann-La Roche Ag |
Anti alfa-sinukleinska protitelesa in postopki uporabe
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
JP6817064B2
(ja)
|
2013-11-27 |
2021-01-20 |
ザイムワークス,インコーポレイテッド |
Her2を標的とする二重特異性抗原結合性コンストラクト
|
JP6549143B2
(ja)
|
2013-12-09 |
2019-07-24 |
アラコス インコーポレイテッド |
抗シグレック−8抗体およびその使用の方法
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
CA2933881A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
KR20160099092A
(ko)
|
2013-12-17 |
2016-08-19 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
MX2016007208A
(es)
|
2013-12-20 |
2016-07-21 |
Hoffmann La Roche |
Anticuerpos anti-tau(ps422) humanizados y metodos de uso.
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
BR112016013849A2
(pt)
|
2014-01-03 |
2017-10-10 |
Hoffmann La Roche |
conjugados de anticorpos biespecíficos antihapteno/antirreceptores da barreira hematoencefálica, seus usos, e formulação farmacêutica
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ.ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
CA2930046A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked polypeptide toxin-antibody conjugates
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
JP2017503803A
(ja)
|
2014-01-10 |
2017-02-02 |
シャンハイ バーディー バイオテック インコーポレイテッド |
Egfr発現腫瘍を処置するための化合物及び組成物
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
KR20160104727A
(ko)
|
2014-01-16 |
2016-09-05 |
아카데미아 시니카 |
암의 치료 및 검출을 위한 조성물 및 방법
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
UA119863C2
(uk)
|
2014-01-24 |
2019-08-27 |
Нгм Біофармасьютікалс, Інк. |
Антитіло або його фрагмент, що зв'язується з бета-клото
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JP2017505305A
(ja)
|
2014-01-24 |
2017-02-16 |
ジェネンテック, インコーポレイテッド |
抗steap1抗体及びイムノコンジュゲートを使用する方法
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
PL3102230T3
(pl)
|
2014-02-08 |
2021-11-15 |
F.Hoffmann-La Roche Ag |
Sposoby leczenia choroby Alzheimera
|
MX2016010433A
(es)
|
2014-02-12 |
2016-09-22 |
Genentech Inc |
Anticuerpos anti-jagged1 y metodos de uso.
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−8関連疾患を処置するための方法および組成物
|
US10435694B2
(en)
|
2014-03-14 |
2019-10-08 |
Genentech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
JP2017516458A
(ja)
|
2014-03-24 |
2017-06-22 |
ジェネンテック, インコーポレイテッド |
c−met拮抗剤による癌治療及びc−met拮抗剤のHGF発現との相関
|
CA2939246A1
(en)
|
2014-03-27 |
2015-10-01 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
EP3129767B1
(en)
|
2014-03-27 |
2021-09-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
PT3126394T
(pt)
|
2014-03-31 |
2019-12-19 |
Hoffmann La Roche |
Anticorpos anti-ox40 e métodos de utilização
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
BR112016024319B1
(pt)
|
2014-04-18 |
2024-01-23 |
Acceleron Pharma Inc |
USO DE UMA COMPOSIÇÃO COMPREENDENDO UM ANTAGONISTA DE ActRII PARA A FABRICAÇÃO DE UM MEDICAMENTO PARA TRATAR OU PREVINIR UMA COMPLICAÇÃO DE ANEMIA FALCIFORME
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
CA2983794A1
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
MA49708A
(fr)
|
2014-04-30 |
2020-06-03 |
Pfizer |
Dérivés de dihétérocycle liés à cycloalkyle
|
TW201623337A
(zh)
|
2014-05-01 |
2016-07-01 |
建南德克公司 |
抗-因子d抗體變異體及其用途
|
CN106415269B
(zh)
|
2014-05-08 |
2020-11-27 |
贵州美鑫达医疗科技有限公司 |
直接免疫组织化学测定
|
BR112016027222A2
(pt)
|
2014-05-22 |
2018-01-30 |
Genentech Inc |
anticorpos isolados, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento de um indivíduo com um câncer, de inibição da proliferação de uma célula, de detecção de gpc3 humano e de detecção de um câncer
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
KR20170005142A
(ko)
|
2014-05-27 |
2017-01-11 |
아카데미아 시니카 |
증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
|
EP3149037A4
(en)
|
2014-05-27 |
2018-01-10 |
Academia Sinica |
Anti-her2 glycoantibodies and uses thereof
|
EP3149036A4
(en)
|
2014-05-27 |
2017-12-27 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP7063538B2
(ja)
|
2014-05-28 |
2022-05-09 |
アカデミア シニカ |
抗TNFα糖操作抗体群およびその使用
|
KR20170010785A
(ko)
|
2014-06-11 |
2017-02-01 |
제넨테크, 인크. |
항-lgr5 항체 및 이의 용도
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
BR122023023170A2
(pt)
|
2014-06-13 |
2024-02-20 |
Acceleron Pharma Inc. |
Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
US10308944B2
(en)
|
2014-07-03 |
2019-06-04 |
Genentech, Inc. |
Polypeptide expression systems
|
EP3164194B1
(en)
|
2014-07-03 |
2021-11-24 |
Yale University |
Dickkopf2 (dkk2) inhibition suppresses tumor formation
|
ES2910446T3
(es)
|
2014-07-09 |
2022-05-12 |
Birdie Biopharmaceuticals Inc |
Combinaciones anti-PD-L1 para tratar tumores
|
CN112546231A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
SG11201700207WA
(en)
|
2014-07-11 |
2017-02-27 |
Genentech Inc |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Cd33キメラ抗原受容体を使用する癌の処置
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
RU2751660C2
(ru)
|
2014-07-21 |
2021-07-15 |
Новартис Аг |
Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
MA50584A
(fr)
|
2014-08-04 |
2020-09-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
|
CA3090240A1
(en)
|
2014-08-08 |
2016-02-11 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
CN107108744B
(zh)
|
2014-08-19 |
2020-09-25 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
CA2959141A1
(en)
|
2014-08-28 |
2016-03-03 |
Bioatla, Llc |
Conditionally active chimeric antigen receptors for modified t-cells
|
TR201907471T4
(tr)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
TWI745275B
(zh)
|
2014-09-08 |
2021-11-11 |
中央研究院 |
使用醣脂激活人類iNKT細胞
|
EP3191521A2
(en)
|
2014-09-12 |
2017-07-19 |
F. Hoffmann-La Roche AG |
Cysteine engineered antibodies and conjugates
|
CA2958479A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
CN113698488A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
CN106794247B
(zh)
|
2014-09-15 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
抗体配制剂
|
BR112017004953A2
(pt)
|
2014-09-17 |
2017-12-05 |
Genentech Inc |
imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
EP3215850B1
(en)
|
2014-11-03 |
2019-07-03 |
F. Hoffmann-La Roche AG |
Assays for detecting t cell immune subsets and methods of use thereof
|
US20160160290A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
RU2017119185A
(ru)
|
2014-11-05 |
2018-12-05 |
Дженентек, Инк. |
Антитела против fgfr2/3 и способы их применения
|
EP3215527A4
(en)
|
2014-11-05 |
2018-04-18 |
Annexon, Inc. |
Humanized anti-complement factor c1q antibodies and uses thereof
|
RU2020141422A
(ru)
|
2014-11-05 |
2021-01-13 |
Дженентек, Инк. |
Способы получения двуцепочечных белков в бактериях
|
JP6875276B2
(ja)
|
2014-11-05 |
2021-05-19 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
EA201791029A1
(ru)
|
2014-11-10 |
2017-12-29 |
Дженентек, Инк. |
Антитела против интерлейкина-33 и их применение
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
MX2017006250A
(es)
|
2014-11-14 |
2017-11-17 |
Hoffmann La Roche |
Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf.
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
JP2018501202A
(ja)
|
2014-11-19 |
2018-01-18 |
ネステク ソシエテ アノニム |
セロトニン、トリプトファン、及びキヌレニンの代謝産物に対する抗体及びその使用
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
CA2966566C
(en)
|
2014-11-20 |
2024-03-19 |
F. Hoffmann-La Roche Ag |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
RU2747011C2
(ru)
|
2014-11-20 |
2021-04-23 |
Ф.Хоффманн-Ля Рош Аг |
Общие легкие цепи и способы их применения
|
US20170355779A1
(en)
|
2014-11-27 |
2017-12-14 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
WO2016087514A1
(en)
|
2014-12-02 |
2016-06-09 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
HUE045216T2
(hu)
|
2014-12-05 |
2019-12-30 |
Hoffmann La Roche |
Anti-CD79B antitestek és alkalmazási eljárások
|
SG11201703750XA
(en)
|
2014-12-10 |
2017-06-29 |
Genentech Inc |
Blood brain barrier receptor antibodies and methods of use
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
EP3034130B1
(en)
|
2014-12-19 |
2019-12-04 |
Althia Health, S.L. |
Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
|
EA201791366A1
(ru)
|
2014-12-19 |
2018-02-28 |
Чугаи Сейяку Кабусики Кайся |
Антитела к c5 и способы их применения
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
WO2016117346A1
(en)
|
2015-01-22 |
2016-07-28 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
WO2016118961A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
EP3250590B1
(en)
|
2015-01-30 |
2021-09-15 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced anti-ssea4 antibody efficacy
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107108729A
(zh)
|
2015-02-05 |
2017-08-29 |
中外制药株式会社 |
包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用
|
CA2976593A1
(en)
|
2015-02-23 |
2016-09-01 |
Seagull Therapeutics Sas |
Non-natural semaphorins 3 and their medical use
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
SI3265557T1
(sl)
|
2015-03-06 |
2020-02-28 |
F. Hoffmann-La Roche Ag |
Ultraprečiščena DsbA in DsbC ter postopki njune izdelave in uporabe
|
WO2016149276A1
(en)
|
2015-03-16 |
2016-09-22 |
Genentech, Inc. |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
EP3271401A4
(en)
|
2015-03-18 |
2018-11-21 |
Immunobiochem Corporation |
Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
MA53400A
(fr)
|
2015-04-06 |
2021-08-04 |
Acceleron Pharma Inc |
Hétéromultimères alk7: actriib et leurs utilisations
|
WO2016164480A1
(en)
|
2015-04-07 |
2016-10-13 |
Genentech, Inc. |
Antigen binding complex having agonistic activity and methods of use
|
EP3280441B1
(en)
|
2015-04-07 |
2021-09-29 |
Alector LLC |
Anti-sortilin antibodies and methods of use thereof
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
KR20180018507A
(ko)
|
2015-04-20 |
2018-02-21 |
톨레로 파마수티컬스, 인크. |
미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
|
CN113552350A
(zh)
|
2015-04-21 |
2021-10-26 |
基因泰克公司 |
用于前列腺癌分析的组合物和方法
|
GB201506870D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
EP3288981A1
(en)
|
2015-05-01 |
2018-03-07 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
WO2016178876A2
(en)
|
2015-05-01 |
2016-11-10 |
Cocrystal Pharma, Inc. |
Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
IL255312B
(en)
|
2015-05-12 |
2022-08-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist
|
EP3298021B1
(en)
|
2015-05-18 |
2019-05-01 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs having increased bioavailability
|
EP3303400B1
(en)
|
2015-05-28 |
2020-09-09 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
CA2984638A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
JP2018520658A
(ja)
|
2015-05-29 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
ヒト化抗エボラウイルス糖タンパク質抗体及びその使用
|
EP3708681A1
(en)
|
2015-05-29 |
2020-09-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
EP3302467A4
(en)
|
2015-05-31 |
2019-01-02 |
Curegenix Corporation |
Combination compositions for immunotherapy
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
PE20180317A1
(es)
|
2015-06-05 |
2018-02-09 |
Genentech Inc |
Anticuerpos anti-tau y metodos de uso
|
EP3303397A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201709934A
(zh)
|
2015-06-15 |
2017-03-16 |
建南德克公司 |
抗體及免疫結合物
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
IL256079B2
(en)
|
2015-06-16 |
2024-01-01 |
Genentech Inc |
Human antibodies with improved affinity to FCRH5 - and methods of use
|
KR20180012859A
(ko)
|
2015-06-17 |
2018-02-06 |
제넨테크, 인크. |
항-her2 항체 및 이용 방법
|
CA2986263A1
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
EP3744732A1
(en)
|
2015-06-24 |
2020-12-02 |
F. Hoffmann-La Roche AG |
Humanized anti-tau(ps422) antibodies and methods of use
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
EP3514174B1
(en)
|
2015-06-29 |
2021-03-31 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
EP4378957A2
(en)
|
2015-07-29 |
2024-06-05 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
EP3964528A1
(en)
|
2015-07-29 |
2022-03-09 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
KR20180034538A
(ko)
|
2015-08-03 |
2018-04-04 |
톨레로 파마수티컬스, 인크. |
암의 치료를 위한 병행 요법
|
US9884900B2
(en)
|
2015-08-04 |
2018-02-06 |
Acceleron Pharma Inc. |
Methods for treating Janus kinase-associated disorders by administering soluble transforming growth factor beta type II receptor
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
KR20180050321A
(ko)
|
2015-08-07 |
2018-05-14 |
이미지냅 인코포레이티드 |
분자를 표적화하기 위한 항원 결합 구조체
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3341415B1
(en)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusine antibodies and uses thereof
|
CN115960235A
(zh)
|
2015-08-28 |
2023-04-14 |
艾利妥 |
抗siglec-7抗体及其使用方法
|
CN108350605A
(zh)
|
2015-09-04 |
2018-07-31 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
WO2017044811A1
(en)
|
2015-09-11 |
2017-03-16 |
Bruce Andrien |
Recombinant glycosylated eculizumab and eculizumab variants
|
BR112018002432A2
(pt)
|
2015-09-18 |
2018-09-18 |
Chugai Pharmaceutical Co Ltd |
anticorpos de ligação à il-8 e usos dos mesmos
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
BR112018005737A2
(pt)
|
2015-09-23 |
2018-10-09 |
Genentech Inc |
anticorpos, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo, para reduzir ou inibir a angiogênese, para tratar um distúrbio associado à angiogênese, para inibir a permeabilidade vascular, composição, conjugado de anticorpo, proteína de fusão, para identificar uma alteração de resíduos, utilização do anticorpo, utilização do conjugado e utilização da proteína
|
RU2732591C2
(ru)
|
2015-09-25 |
2020-09-21 |
Дженентек, Инк. |
Анти-tigit антитела и способы применения
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
BR112018006237A2
(pt)
|
2015-09-29 |
2018-10-09 |
Celgene Corp |
proteínas de ligação a pd-1 e métodos de uso das mesmas
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
CN108026179A
(zh)
|
2015-10-02 |
2018-05-11 |
豪夫迈·罗氏有限公司 |
结合间皮素和cd3的双特异性t细胞活化性抗原结合分子
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
CN115746143A
(zh)
|
2015-10-02 |
2023-03-07 |
豪夫迈·罗氏有限公司 |
对共刺激性tnf受体特异性的双特异性抗体
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
EP3356409A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
SI3356411T1
(sl)
|
2015-10-02 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Bispecifična protitelesa, specifična za PD1 in TIM3
|
PE20181092A1
(es)
|
2015-10-02 |
2018-07-09 |
Hoffmann La Roche |
Anticuerpos anti-pd1 y metodos de uso
|
CN108431038A
(zh)
|
2015-10-06 |
2018-08-21 |
豪夫迈·罗氏有限公司 |
治疗多发性硬化的方法
|
CN117069841A
(zh)
|
2015-10-06 |
2023-11-17 |
艾利妥 |
抗trem2抗体及其使用方法
|
PE20181349A1
(es)
|
2015-10-07 |
2018-08-22 |
Hoffmann La Roche |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
|
US11203634B2
(en)
|
2015-10-07 |
2021-12-21 |
Alexion Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3365442B8
(en)
|
2015-10-23 |
2022-06-08 |
Fred Hutchinson Cancer Center |
Methods to create chemically-induced dimerizing protein systems for regulation of cellular events
|
KR20180085723A
(ko)
|
2015-10-28 |
2018-07-27 |
예일 유니버시티 |
인간화 항-dkk2 항체 및 이의 용도
|
SG11201803567XA
(en)
|
2015-10-29 |
2018-05-30 |
Alector Llc |
Anti-siglec-9 antibodies and methods of use thereof
|
EP4015533A1
(en)
|
2015-10-29 |
2022-06-22 |
F. Hoffmann-La Roche AG |
Anti-variant fc-region antibodies and methods of use
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
JP2018536650A
(ja)
|
2015-10-30 |
2018-12-13 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体変異体コンジュゲート及びその使用
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
KR102162324B1
(ko)
|
2015-10-30 |
2020-10-07 |
제넨테크, 인크. |
항-HtrA1 항체 및 이의 사용 방법
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
CN108601752A
(zh)
|
2015-12-03 |
2018-09-28 |
安吉奥斯医药品有限公司 |
用于治疗mtap缺失型癌症的mat2a抑制剂
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
LT3390441T
(lt)
|
2015-12-15 |
2021-11-10 |
Gilead Sciences, Inc. |
Žmogaus imunodeficito virusą neutralizuojantys antikūnai
|
JP2019503349A
(ja)
|
2015-12-17 |
2019-02-07 |
ノバルティス アーゲー |
Pd−1に対する抗体分子およびその使用
|
KR20180094977A
(ko)
|
2015-12-17 |
2018-08-24 |
노파르티스 아게 |
c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
|
SG10201709415WA
(en)
|
2015-12-18 |
2017-12-28 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
KR20180093078A
(ko)
|
2015-12-30 |
2018-08-20 |
제넨테크, 인크. |
단백질 제제를 위한 트립토판 유도체의 용도
|
KR20180098625A
(ko)
|
2015-12-30 |
2018-09-04 |
제넨테크, 인크. |
분해가 감소된 폴리소르베이트를 갖는 제형
|
CN107531795B
(zh)
|
2016-01-05 |
2021-01-19 |
江苏恒瑞医药股份有限公司 |
Pcsk9抗体、其抗原结合片段及其医药用途
|
CN108368179B
(zh)
|
2016-01-08 |
2022-08-23 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗cea/抗cd3双特异性抗体治疗cea阳性癌症的方法
|
US20190016791A1
(en)
|
2016-01-20 |
2019-01-17 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
US11513127B2
(en)
|
2016-01-25 |
2022-11-29 |
Genentech, Inc. |
Methods for assaying T-cell dependent bispecific antibodies
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
US10982136B2
(en)
|
2016-02-26 |
2021-04-20 |
The Regents Of The University Of California |
Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters
|
AU2017225854B2
(en)
|
2016-02-29 |
2020-11-19 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
SG11201807489PA
(en)
|
2016-03-04 |
2018-09-27 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
EP3423493A2
(en)
|
2016-03-04 |
2019-01-09 |
Alector LLC |
Anti-trem1 antibodies and methods of use thereof
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
CR20180453A
(es)
|
2016-03-22 |
2018-12-05 |
Hoffmann La Roche |
Moleculas biespecíficas de células t activadas por proteasas
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
JP6943872B2
(ja)
|
2016-03-25 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
多重全抗体及び抗体複合体化薬物定量化アッセイ
|
AU2017239637A1
(en)
|
2016-03-29 |
2018-11-15 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
CA3021086C
(en)
|
2016-04-15 |
2023-10-17 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
KR20180134385A
(ko)
|
2016-04-15 |
2018-12-18 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
CN109154027A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
BR112018071683A2
(pt)
|
2016-04-22 |
2019-02-19 |
Obi Pharma, Inc. |
método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
|
UA123323C2
(uk)
|
2016-05-02 |
2021-03-17 |
Ф. Хоффманн-Ля Рош Аг |
Димерний злитий поліпептид
|
US20190151346A1
(en)
|
2016-05-10 |
2019-05-23 |
INSERM (Institute National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
WO2017194442A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
TW202208441A
(zh)
|
2016-05-13 |
2022-03-01 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
AU2017268234A1
(en)
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
CN109313200B
(zh)
|
2016-05-27 |
2022-10-04 |
豪夫迈·罗氏有限公司 |
用于表征位点特异性抗体-药物缀合物的生物分析性方法
|
US10851159B2
(en)
|
2016-06-02 |
2020-12-01 |
Bloom Diagnostics Ag |
Antibodies that bind to human anti-Müllerian hormone (AMH) and their uses
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
JP7043425B2
(ja)
|
2016-06-06 |
2022-03-29 |
ジェネンテック, インコーポレイテッド |
シルベストロール抗体-薬物コンジュゲート及び使用方法
|
EP3472177A2
(en)
|
2016-06-17 |
2019-04-24 |
F. Hoffmann-La Roche AG |
Purification of multispecific antibodies
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
CA3030841A1
(en)
|
2016-07-14 |
2018-01-18 |
Fred Hutchinson Cancer Research Center |
Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
|
PL3496739T3
(pl)
|
2016-07-15 |
2021-10-11 |
Acceleron Pharma Inc. |
Kompozycje zawierające polipeptydy actriia do stosowania w leczeniu nadciśnienia płucnego
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-05-16 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
MX2019001043A
(es)
|
2016-07-27 |
2019-09-26 |
Acceleron Pharma Inc |
Metodos y composiciones para el tratamiento de la mielofibrosis.
|
WO2018022933A1
(en)
|
2016-07-27 |
2018-02-01 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
SG11201900677SA
(en)
|
2016-07-28 |
2019-02-27 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
CN109415444B
(zh)
|
2016-07-29 |
2024-03-01 |
中外制药株式会社 |
显示增加的备选fviii辅因子功能活性的双特异性抗体
|
US11643456B2
(en)
|
2016-07-29 |
2023-05-09 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
JP2019527696A
(ja)
|
2016-08-01 |
2019-10-03 |
ノバルティス アーゲー |
プロm2マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
MX2019001572A
(es)
|
2016-08-15 |
2019-08-29 |
Genentech Inc |
Método de cromatografía para cuantificar un tensioactivo no iónico en una composición que comprende el tensioactivo no iónico y un polipéptido.
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
US11235076B2
(en)
|
2016-08-29 |
2022-02-01 |
Fred Hutchinson Cancer Research Center |
Chelating platform for delivery of radionuclides
|
SG10202100683RA
(en)
|
2016-08-31 |
2021-03-30 |
Oncotherapy Science Inc |
Monoclonal antibody against melk and utilization thereof
|
EP3509595B1
(en)
|
2016-09-06 |
2022-11-02 |
The Regents of The University of California |
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
|
WO2018049083A1
(en)
|
2016-09-07 |
2018-03-15 |
The Regents Of The University Of California |
Antibodies to oxidation-specific epitopes
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
US10751414B2
(en)
|
2016-09-19 |
2020-08-25 |
Celgene Corporation |
Methods of treating psoriasis using PD-1 binding antibodies
|
CN116731197A
(zh)
|
2016-09-19 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
FI3528838T3
(fi)
|
2016-09-23 |
2023-10-02 |
Hoffmann La Roche |
IL-13-antagonistien käyttöjä atooppisen ihottuman hoitamiseksi
|
JP7323737B2
(ja)
|
2016-09-29 |
2023-08-09 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
液-液抽出による金属イオンの分離
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
EP3522934A4
(en)
|
2016-10-05 |
2020-04-15 |
Acceleron Pharma Inc. |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF RENOPATHY
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
TWI762516B
(zh)
|
2016-10-06 |
2022-05-01 |
日商腫瘤療法 科學股份有限公司 |
針對fzd10之單株抗體及其用途
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
ES2848206T3
(es)
|
2016-10-19 |
2021-08-05 |
Alexion Pharma Inc |
Un método de cuantificar C5 sin unir en una muestra
|
WO2018075761A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
JP2020500508A
(ja)
|
2016-10-28 |
2020-01-16 |
バンヤン・バイオマーカーズ・インコーポレーテッド |
ユビキチンc末端ヒドロラーゼl1(uch−l1)およびグリア線維酸性タンパク質(gfap)に対する抗体および関連する方法
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
WO2018094414A1
(en)
|
2016-11-21 |
2018-05-24 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
CN117820467A
(zh)
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
KR102587130B1
(ko)
|
2016-12-07 |
2023-10-11 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
CN110114674B
(zh)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
确定肿瘤样品中存在靶抗原的方法
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
EP3554542A1
(en)
|
2016-12-19 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
MX2019006954A
(es)
|
2016-12-20 |
2019-08-01 |
Hoffmann La Roche |
Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137).
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
CR20190309A
(es)
|
2017-01-03 |
2019-08-21 |
Hoffmann La Roche |
Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CN110709419B
(zh)
|
2017-01-06 |
2023-11-28 |
博奥信生物技术(南京)有限公司 |
Erbb2抗体及其用途
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
CR20190387A
(es)
|
2017-02-10 |
2019-09-25 |
Genentech Inc |
Anticuerpos contra triptasa, composiciones de estos y usos de estos
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
TW201837467A
(zh)
|
2017-03-01 |
2018-10-16 |
美商建南德克公司 |
用於癌症之診斷及治療方法
|
CN118063619A
(zh)
|
2017-03-02 |
2024-05-24 |
诺华股份有限公司 |
工程化的异源二聚体蛋白质
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
AU2018240375C1
(en)
|
2017-03-22 |
2024-02-01 |
Ascendis Pharma A/S |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
JP7227151B2
(ja)
|
2017-03-22 |
2023-02-21 |
ジェネンテック, インコーポレイテッド |
眼障害の治療のために最適化された抗体組成物
|
CR20190440A
(es)
|
2017-03-27 |
2019-11-12 |
Hoffmann La Roche |
Receptores de unión a antígeno mejorados
|
KR20190133017A
(ko)
|
2017-03-27 |
2019-11-29 |
에프. 호프만-라 로슈 아게 |
개선된 항원 결합 수용체 구성
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
CN110382525B
(zh)
|
2017-04-03 |
2023-10-20 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
JP7247101B2
(ja)
|
2017-04-03 |
2023-03-28 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Steap-1に結合する抗体
|
AU2018247765B2
(en)
|
2017-04-03 |
2023-11-23 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of an Anti-PD-1 antibody with a mutant IL-2 or with IL-15
|
SG11201908787WA
(en)
|
2017-04-04 |
2019-10-30 |
Hoffmann La Roche |
Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
|
LT3606954T
(lt)
|
2017-04-05 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antikūnai
|
IL268527B2
(en)
|
2017-04-05 |
2024-03-01 |
Hoffmann La Roche |
Bispecific antibodies bind to PD1 and LAG3 specifically
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
CN108728444A
(zh)
|
2017-04-18 |
2018-11-02 |
长春华普生物技术股份有限公司 |
免疫调节性多核苷酸及其应用
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
EP3615569A1
(en)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
CN110831628A
(zh)
|
2017-05-05 |
2020-02-21 |
爱乐科斯公司 |
用于治疗过敏性眼病的方法和组合物
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
EP3625258A1
(en)
|
2017-05-16 |
2020-03-25 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
EP3630830A1
(en)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
EP3630829A1
(en)
|
2017-06-02 |
2020-04-08 |
H. Hoffnabb-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
WO2018237157A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
CA3064966A1
(en)
|
2017-06-30 |
2019-01-03 |
Zymeworks Inc. |
Stabilized chimeric fabs
|
TWI820031B
(zh)
|
2017-07-11 |
2023-11-01 |
美商坎伯斯治療有限責任公司 |
結合人類cd137之促效劑抗體及其用途
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
WO2019023347A1
(en)
|
2017-07-26 |
2019-01-31 |
Forty Seven, Inc. |
ANTI-SIRP-ALPHA ANTIBODIES AND ASSOCIATED METHODS
|
KR20200036889A
(ko)
|
2017-07-28 |
2020-04-07 |
에프. 호프만-라 로슈 아게 |
이중특이성 항체 제형
|
EP3589658A1
(en)
|
2017-08-03 |
2020-01-08 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
RS64419B1
(sr)
|
2017-08-03 |
2023-09-29 |
Alector Llc |
Anti-trem2 antitela i postupci za njihovu upotrebu
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
EP3684413A1
(en)
|
2017-09-20 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
MA50667A
(fr)
|
2017-09-29 |
2020-08-05 |
Chugai Pharmaceutical Co Ltd |
Molécule multispécifique de liaison à l'antigène ayant une activité de substitution de la fonction de cofacteur du facteur viii de coagulation sanguine (fviii), et formulation pharmaceutique contenant ladite molécule en tant que principe actif
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
US20200237766A1
(en)
|
2017-10-13 |
2020-07-30 |
Tolero Pharmaceuticals, Inc. |
Pkm2 activators in combination with reactive oxygen species for treatment of cancer
|
AU2018353420A1
(en)
|
2017-10-20 |
2020-04-16 |
F. Hoffmann-La Roche Ag |
Method for generating multispecific antibodies from monospecific antibodies
|
JP7438942B2
(ja)
|
2017-10-30 |
2024-02-27 |
エフ. ホフマン-ラ ロシュ アーゲー |
単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
MX2020004573A
(es)
|
2017-11-01 |
2020-09-25 |
Hoffmann La Roche |
Terapia de combinacion con agonistas de ox40 dirigidos.
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
PE20210844A1
(es)
|
2017-11-01 |
2021-05-10 |
Hoffmann La Roche |
Contorsbodies 2 + biespecificos
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
EP3704146B1
(en)
|
2017-11-01 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Trifab-contorsbody
|
EP3707510B1
(en)
|
2017-11-06 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
KR20200099135A
(ko)
|
2017-12-14 |
2020-08-21 |
에프. 호프만-라 로슈 아게 |
Cea cd3 이중특이성 항체 및 pd-1 축 결합 길항제의 암 치료를 위한 투약 요법에서의 용도
|
JP7394058B2
(ja)
|
2017-12-21 |
2023-12-07 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
|
CN111492243A
(zh)
|
2017-12-21 |
2020-08-04 |
豪夫迈·罗氏有限公司 |
用于新颖抗原结合模块的特异性测试的car-t细胞测定法
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
TW201930350A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對pd-l1之抗體及其變異體
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
US20200339686A1
(en)
|
2018-01-16 |
2020-10-29 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
安定化された免疫グロブリンドメイン
|
WO2019152715A1
(en)
|
2018-01-31 |
2019-08-08 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
EP3749361A1
(en)
|
2018-02-08 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen-binding molecules and methods of use
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
KR20230142806A
(ko)
|
2018-02-09 |
2023-10-11 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
CA3092108A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
EP3759491A1
(en)
|
2018-03-01 |
2021-01-06 |
H. Hoffnabb-La Roche Ag |
Specificity assay for novel target antigen binding moieties
|
KR20200132913A
(ko)
|
2018-03-13 |
2020-11-25 |
에프. 호프만-라 로슈 아게 |
4-1bb 작용제와 항-cd20 항체의 치료 조합
|
MX2020009512A
(es)
|
2018-03-13 |
2020-10-22 |
Hoffmann La Roche |
Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados.
|
WO2019174617A1
(en)
|
2018-03-14 |
2019-09-19 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
WO2019183266A1
(en)
|
2018-03-21 |
2019-09-26 |
ALX Oncology Inc. |
Antibodies against signal-regulatory protein alpha and methods of use
|
MX2020010028A
(es)
|
2018-03-29 |
2020-10-14 |
Genentech Inc |
Actividad lactogenica modulada en celulas de mamifero.
|
JP7104458B2
(ja)
|
2018-04-02 |
2022-07-21 |
上海博威生物医薬有限公司 |
リンパ球活性化遺伝子-3(lag-3)結合抗体およびその使用
|
WO2019192973A1
(en)
|
2018-04-04 |
2019-10-10 |
F. Hoffmann-La Roche Ag |
Diagnostic assays to detect tumor antigens in cancer patients
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
JP2021520209A
(ja)
|
2018-04-04 |
2021-08-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
癌患者における腫瘍抗原を検出するための診断アッセイ
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
EP3774900A1
(en)
|
2018-04-13 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
CA3100018A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
JP7460609B2
(ja)
|
2018-05-14 |
2024-04-02 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なインターロイキン-2ポリペプチド及びその使用方法
|
KR102470059B1
(ko)
|
2018-05-18 |
2022-11-22 |
에프. 호프만-라 로슈 아게 |
큰 핵산의 표적화된 세포내 전달
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
CR20200566A
(es)
|
2018-05-25 |
2021-02-19 |
Alector Llc |
Anticuerpos anti-sirpa y metodos de utilización de los mismos
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
JP7372237B2
(ja)
|
2018-06-04 |
2023-10-31 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
US20210246204A1
(en)
|
2018-06-08 |
2021-08-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
WO2019246293A2
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
EP3814377A2
(en)
|
2018-06-29 |
2021-05-05 |
Alector LLC |
Anti-sirp-beta1 antibodies and methods of use thereof
|
JP2021528988A
(ja)
|
2018-07-04 |
2021-10-28 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規の二重特異性アゴニスト4−1bb抗原結合分子
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
KR20230065382A
(ko)
|
2018-07-13 |
2023-05-11 |
알렉터 엘엘씨 |
항-소틸린 항체 및 이들의 사용 방법
|
MX2021000558A
(es)
|
2018-07-18 |
2021-04-13 |
Genentech Inc |
Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un antimetabolito y un agente de platino.
|
SG11202100373VA
(en)
|
2018-07-20 |
2021-02-25 |
Surface Oncology Inc |
Anti-cd112r compositions and methods
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
CA3106535A1
(en)
|
2018-07-27 |
2020-01-30 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
AU2019315226A1
(en)
|
2018-08-03 |
2021-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
MX2021001453A
(es)
|
2018-08-08 |
2021-04-12 |
Genentech Inc |
Uso de derivados de triptofano y l-metionina para una formulacion de proteinas.
|
BR112021002037A2
(pt)
|
2018-08-10 |
2021-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
molécula de ligação de antígeno anti-cd137 e uso da mesma
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
WO2020041360A1
(en)
|
2018-08-21 |
2020-02-27 |
Quidel Corporation |
Dbpa antibodies and uses thereof
|
KR20210057053A
(ko)
|
2018-08-23 |
2021-05-20 |
씨젠 인크. |
항-tigit 항체
|
AU2019331018A1
(en)
|
2018-08-31 |
2021-03-11 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
AR114732A1
(es)
|
2018-09-18 |
2020-10-07 |
Hoffmann La Roche |
Utilización de un inhibidor de catepsina s contra la formación de anticuerpos antifármaco
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
EP3856764A4
(en)
|
2018-09-27 |
2022-11-02 |
Xilio Development, Inc. |
MASKED CYTOKINE POLYPEPTIDES
|
CA3114295A1
(en)
|
2018-09-28 |
2020-04-02 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd40への三価結合を伴う二重特異性抗原結合分子
|
CA3113548A1
(en)
|
2018-10-01 |
2020-04-09 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020086858A1
(en)
|
2018-10-24 |
2020-04-30 |
Genentech, Inc. |
Conjugated chemical inducers of degradation and methods of use
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
JP2022506156A
(ja)
|
2018-11-05 |
2022-01-17 |
ジェネンテック, インコーポレイテッド |
原核宿主細胞における2鎖タンパク質の産生方法
|
SG11202104864QA
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
US20220364171A1
(en)
|
2018-11-23 |
2022-11-17 |
Katholieke Universiteit Leuven |
Predicting a treatment response in inflammatory bowel disease
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
EP3897648B1
(en)
|
2018-12-20 |
2023-08-23 |
Novartis AG |
Extended low dose regimens for mdm2 inhibitors
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
AU2019402163A1
(en)
|
2018-12-20 |
2021-07-08 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
KR20210107721A
(ko)
|
2018-12-21 |
2021-09-01 |
23앤드미 인코포레이티드 |
항-il-36 항체 및 이의 사용 방법
|
WO2020132231A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
SG11202102859TA
(en)
|
2018-12-21 |
2021-04-29 |
Hoffmann La Roche |
Antibodies binding to cd3
|
UA128001C2
(uk)
|
2018-12-21 |
2024-03-06 |
Ф. Хоффманн-Ля Рош Аг |
Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
|
CN113286822A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的超激动性cd28抗原结合分子
|
MX2021007769A
(es)
|
2018-12-26 |
2021-09-23 |
Xilio Dev Inc |
Proteínas de unión anti-ctla4 enmascaradas activables.
|
CN113272327A
(zh)
|
2018-12-30 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
抗兔cd19抗体及其使用方法
|
CA3124837A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
US20220088075A1
(en)
|
2019-02-22 |
2022-03-24 |
The Trustees Of The University Of Pennsylvania |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
KR20210138588A
(ko)
|
2019-03-08 |
2021-11-19 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
CA3133136A1
(en)
|
2019-03-13 |
2020-09-17 |
Merck Patent Gmbh |
Process for the preparation of lipidated proteinaceous structures
|
MA55296A
(fr)
|
2019-03-14 |
2022-03-23 |
Hoffmann La Roche |
Traitement du cancer avec des anticorps bispécifiques de her2xcd3 en combinaison avec un mab anti-her2
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
CN113747895A
(zh)
|
2019-03-22 |
2021-12-03 |
大日本住友制药肿瘤公司 |
包含pkm2调节剂的组合物和用其治疗的方法
|
SG11202110732XA
(en)
|
2019-03-29 |
2021-10-28 |
Atarga Llc |
Anti fgf23 antibody
|
CN113692414A
(zh)
|
2019-04-12 |
2021-11-23 |
豪夫迈·罗氏有限公司 |
使用CEA CD3双特异性抗体和Wnt信号传导抑制剂的癌症治疗
|
EP3952996A1
(en)
|
2019-04-12 |
2022-02-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising lipocalin muteins
|
EP3957325A4
(en)
|
2019-04-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
CHEMERA RECEPTOR RECOGNIZING AN ANTIBODY MODIFICATION SITE
|
KR20220002967A
(ko)
|
2019-04-19 |
2022-01-07 |
제넨테크, 인크. |
항 mertk 항체 및 이의 사용 방법
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
WO2020226986A2
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
TW202108177A
(zh)
|
2019-05-10 |
2021-03-01 |
日商武田藥品工業股份有限公司 |
抗體藥物結合物
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
JP2022532217A
(ja)
|
2019-05-14 |
2022-07-13 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
分離部分及びその使用方法
|
JP2022532385A
(ja)
|
2019-05-16 |
2022-07-14 |
プロサイセデクス インコーポレイティド |
血中のVCAM-1及びα2-マクログロブリンの検出のためのアッセイ方法
|
WO2020232262A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
Assay detection methods for vcam-1 and calprotectin
|
EP3973290A1
(en)
|
2019-05-23 |
2022-03-30 |
ProciseDx Inc. |
Assay methods for the detection of human serum albumin, vitamin d, c-reactive protein, and anti-transglutaminase autoantibody
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
EP3980779A1
(en)
|
2019-06-06 |
2022-04-13 |
ProciseDx Inc. |
Detection of hemoglobin a1c (hba1c) in blood
|
JP2022536839A
(ja)
|
2019-06-11 |
2022-08-19 |
アレクトル エルエルシー |
治療に使用するための抗ソルチリン抗体
|
EP3990922A1
(en)
|
2019-06-25 |
2022-05-04 |
ProciseDx Inc. |
Detection of anti-tnf alpha drug biologics and anti-drug antibodies
|
TW202115124A
(zh)
|
2019-06-26 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
結合至cea之新穎抗原結合分子
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
BR112021026492A2
(pt)
|
2019-06-28 |
2022-02-08 |
Genentech Inc |
Formulações líquidas, formulação liofilizada, artigos de fabricação e método para preparar uma formulação líquida
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
CN114341187A
(zh)
|
2019-07-12 |
2022-04-12 |
中外制药株式会社 |
抗突变型fgfr3抗体及其用途
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
CN114423787A
(zh)
|
2019-07-19 |
2022-04-29 |
昂科里斯庞斯公司 |
免疫调节性抗体及其使用方法
|
EP4003526A2
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
CR20220078A
(es)
|
2019-07-31 |
2022-06-24 |
Alector Llc |
Anticuerpos anti-ms4a4a y métodos de uso de los mismos
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
AU2020349509A1
(en)
|
2019-09-18 |
2022-03-31 |
Genentech, Inc. |
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
|
TW202126699A
(zh)
|
2019-09-20 |
2021-07-16 |
美商建南德克公司 |
用於抗類胰蛋白酶抗體之投藥
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
EP4045090A1
(en)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
AU2020370832A1
(en)
|
2019-10-21 |
2022-05-19 |
Novartis Ag |
TIM-3 inhibitors and uses thereof
|
AU2020381349A1
(en)
|
2019-11-05 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
MX2022006391A
(es)
|
2019-11-26 |
2022-06-24 |
Novartis Ag |
Receptores de antigeno quimerico que se unen a bcma y cd19 y usos de los mismos.
|
CA3158565A1
(en)
|
2019-12-05 |
2021-06-10 |
Tina SCHWABE |
Methods of use of anti-trem2 antibodies
|
US20230035072A1
(en)
|
2019-12-12 |
2023-02-02 |
Alector Llc |
Methods of use of anti-cd33 antibodies
|
AU2020401319A1
(en)
|
2019-12-13 |
2022-06-30 |
Alector Llc |
Anti-MerTK antibodies and methods of use thereof
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
KR20220100963A
(ko)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Hla-a2/mage-a4에 결합하는 항체
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
JP2023509390A
(ja)
|
2019-12-23 |
2023-03-08 |
ジェネンテック, インコーポレイテッド |
アポリポタンパク質l1特異的抗体及びその使用方法
|
BR112022011723A2
(pt)
|
2019-12-27 |
2022-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticorpo anti-ctla-4 e uso do mesmo
|
CA3162009A1
(en)
|
2020-01-09 |
2021-07-15 |
F. Hoffmann-La Roche Ag |
New 4-1bbl trimer-containing antigen binding molecules
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
KR20220128389A
(ko)
|
2020-01-17 |
2022-09-20 |
노파르티스 아게 |
골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
AU2021218927A1
(en)
|
2020-02-10 |
2022-09-22 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
EP4105237A4
(en)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co Ltd |
ANTI-CLDN18.2 ANTIBODIES AND ITS USE
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
JP2023515478A
(ja)
|
2020-02-24 |
2023-04-13 |
アレクトル エルエルシー |
抗trem2抗体の使用方法
|
AU2021225949A1
(en)
|
2020-02-27 |
2022-09-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
KR20220152262A
(ko)
|
2020-03-13 |
2022-11-15 |
제넨테크, 인크. |
항-인터루킨-33 항체 및 이의 용도
|
AU2021236660A1
(en)
|
2020-03-19 |
2022-08-18 |
Genentech, Inc. |
Isoform-selective anti-TGF-beta antibodies and methods of use
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
BR112022018847A2
(pt)
|
2020-03-24 |
2022-11-22 |
Genentech Inc |
Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック, インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
KR20220161375A
(ko)
|
2020-03-31 |
2022-12-06 |
추가이 세이야쿠 가부시키가이샤 |
다중 특이성 항원 결합 분자를 제조하기 위한 방법
|
US20230107644A1
(en)
|
2020-04-01 |
2023-04-06 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
CA3172451A1
(en)
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
IL297060A
(en)
|
2020-04-09 |
2022-12-01 |
Univ Muenchen Tech |
Targeted administration of an inhibitor of mir-21 to macrophages for the treatment of pulmonary fibrosis
|
BR112022020629A2
(pt)
|
2020-04-15 |
2022-11-29 |
Hoffmann La Roche |
Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
|
BR112022020753A2
(pt)
|
2020-04-15 |
2022-12-20 |
Voyager Therapeutics Inc |
Compostos de ligação a tau
|
CN115427443A
(zh)
|
2020-04-24 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
巯基化合物及其衍生物的酶和途径调节
|
JP2023522930A
(ja)
|
2020-04-24 |
2023-06-01 |
ジェネンテック, インコーポレイテッド |
抗CD79b免疫抱合体の使用方法
|
CA3172880A1
(en)
|
2020-04-27 |
2021-11-04 |
Sotirios Tsimikas |
Isoform-independent antibodies to lipoprotein(a)
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
KR20230002261A
(ko)
|
2020-04-28 |
2023-01-05 |
더 락커펠러 유니버시티 |
항-sars-cov-2 중화 항체 및 이의 사용 방법
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁(苏州)生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
WO2021229103A2
(en)
|
2020-05-15 |
2021-11-18 |
Apogenix Ag |
Multi-specific immune modulators
|
AU2021281417A1
(en)
|
2020-05-29 |
2022-12-08 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
JP2023527918A
(ja)
|
2020-06-08 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗hbv抗体及び使用方法
|
KR20230023727A
(ko)
|
2020-06-11 |
2023-02-17 |
제넨테크, 인크. |
나노지단백질-폴리펩티드 접합체 및 조성물, 시스템, 및 이의 사용 방법
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
AU2021293038A1
(en)
|
2020-06-16 |
2023-02-02 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating triple-negative breast cancer
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-TIGIT antibodies and PD-1 spindle-binding antagonists
|
JP2023538716A
(ja)
|
2020-06-19 |
2023-09-11 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd3及びcd19に結合する抗体
|
MX2022015890A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos biespecificos para linfocitos t activados por proteasa.
|
KR20230025665A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
Cd3에 결합하는 항체
|
BR112022025809A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpos, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo, uso do anticorpo, método para tratar uma doença e invenção
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗il-36抗体およびその使用方法
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2021259890A1
(en)
|
2020-06-23 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Agonistic cd28 antigen binding molecules targeting her2
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
CN115916830A
(zh)
|
2020-06-25 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
抗cd3/抗cd28双特异性抗原结合分子
|
US20230272116A1
(en)
|
2020-07-10 |
2023-08-31 |
Hoffmann-La Roche Inc. |
Antibodies which bind to cancer cells and target radionuclides to said cells
|
EP4179332A1
(en)
|
2020-07-13 |
2023-05-17 |
Genentech, Inc. |
Cell-based methods for predicting polypeptide immunogenicity
|
JP2023534214A
(ja)
|
2020-07-16 |
2023-08-08 |
ノバルティス アーゲー |
抗ベータセルリン抗体、その断片、及び多重特異性結合分子
|
PE20231300A1
(es)
|
2020-07-17 |
2023-08-24 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
JP2023535409A
(ja)
|
2020-07-21 |
2023-08-17 |
ジェネンテック, インコーポレイテッド |
Brm分解の抗体コンジュゲート化化学的誘導物質及びbrm分解の方法
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
EP4192942A1
(en)
|
2020-08-07 |
2023-06-14 |
Genentech, Inc. |
T cell-based methods for predicting polypeptide immunogenicity
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
CA3192323A1
(en)
|
2020-09-14 |
2022-03-17 |
Julie MACOIN |
Antibodies that bind to il1rap and uses thereof
|
MX2023003133A
(es)
|
2020-09-24 |
2023-03-23 |
Hoffmann La Roche |
Prevencion o mitigacion de efectos adversos relacionados con el anticuerpo biespecifico de linfocitos t.
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
CA3190782A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhibitors
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
CA3199319A1
(en)
|
2020-10-22 |
2022-04-28 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
EP4237450A1
(en)
|
2020-10-30 |
2023-09-06 |
F. Hoffmann-La Roche AG |
Treatment of cancer using a cea cd3 bispecific antibody and a tgfbeta signaling inhibitor
|
US20220162329A1
(en)
|
2020-11-04 |
2022-05-26 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
JP2023548064A
(ja)
|
2020-11-04 |
2023-11-15 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体及び抗cd79b抗体薬物コンジュゲートによる処置のための投与
|
WO2022098628A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
CN116472288A
(zh)
|
2020-11-06 |
2023-07-21 |
诺华股份有限公司 |
抗体Fc变体
|
EP4240415A1
(en)
|
2020-11-08 |
2023-09-13 |
Seagen Inc. |
Combination-therapy antibody drug conjugate with immune cell inhibitor
|
JP7397996B2
(ja)
|
2020-11-09 |
2023-12-13 |
武田薬品工業株式会社 |
抗体薬物コンジュゲート
|
CA3196810A1
(en)
|
2020-11-10 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
KR20230109674A
(ko)
|
2020-11-16 |
2023-07-20 |
에프. 호프만-라 로슈 아게 |
Fab 고 만노스 당형
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
AU2021392039A1
(en)
|
2020-12-02 |
2023-06-29 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
JP2023551563A
(ja)
|
2020-12-04 |
2023-12-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
pH依存性変異体インターロイキン-2ポリペプチド
|
AU2021395729A1
(en)
|
2020-12-07 |
2023-07-13 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
KR20230118128A
(ko)
|
2020-12-07 |
2023-08-10 |
유씨비 바이오파마 에스알엘 |
인터루킨-22에 대한 항체
|
CR20230263A
(es)
|
2020-12-17 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de estos
|
EP4271482A2
(en)
|
2020-12-31 |
2023-11-08 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
AU2022206061A1
(en)
|
2021-01-06 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
AU2022207615A1
(en)
|
2021-01-12 |
2023-07-13 |
F. Hoffmann-La Roche Ag |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
MX2023008083A
(es)
|
2021-01-13 |
2023-07-13 |
Hoffmann La Roche |
Tratamiento conjunto.
|
US20220227844A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
MX2023008485A
(es)
|
2021-01-20 |
2023-07-28 |
Oncoresponse Inc |
Anticuerpos inmunomoduladores y usos de estos.
|
CN116917326A
(zh)
|
2021-01-22 |
2023-10-20 |
博泰康医药公司 |
抗her-2/trop-2构建体及其用途
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
CN117440832A
(zh)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
包括抗bcma抗体的抗体-药物缀合物
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
CN116981696A
(zh)
|
2021-03-18 |
2023-10-31 |
艾莱克特有限责任公司 |
抗tmem106b抗体及其使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
GB202104104D0
(en)
|
2021-03-24 |
2021-05-05 |
Liliumx Ltd |
Platform and method
|
US20240166731A1
(en)
|
2021-03-26 |
2024-05-23 |
Janssen Biotech, Inc. |
Humanized antibodies against paired helical filament tau and uses thereof
|
JP2024512709A
(ja)
|
2021-03-30 |
2024-03-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化ポリペプチド
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20230165911A
(ko)
|
2021-04-09 |
2023-12-05 |
씨젠 인크. |
항-tigit 항체를 사용한 암의 치료 방법
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
KR20230173164A
(ko)
|
2021-04-19 |
2023-12-26 |
제넨테크, 인크. |
변형된 포유류 세포
|
WO2022223651A1
(en)
|
2021-04-23 |
2022-10-27 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of nk cell engaging agent-related adverse effects
|
JP2024517535A
(ja)
|
2021-04-30 |
2024-04-23 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体と抗cd79b抗体薬物コンジュゲートを用いた併用治療の投与
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
AR125732A1
(es)
|
2021-05-03 |
2023-08-09 |
UCB Biopharma SRL |
Anticuerpos anti-trem1
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
KR20240007928A
(ko)
|
2021-05-14 |
2024-01-17 |
제넨테크, 인크. |
Trem2의 효능제
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
EP4351582A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
IL308633A
(en)
|
2021-06-25 |
2024-01-01 |
Chugai Pharmaceutical Co Ltd |
Use of anti-CTLA-4 antibodies
|
IL309115A
(en)
|
2021-06-25 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Anti-CTLA-4 antibodies
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
WO2023288241A1
(en)
|
2021-07-14 |
2023-01-19 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
WO2023001884A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
KR20240038008A
(ko)
|
2021-07-28 |
2024-03-22 |
에프. 호프만-라 로슈 아게 |
암 치료 방법 및 조성물
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
KR20240049296A
(ko)
|
2021-08-27 |
2024-04-16 |
제넨테크, 인크. |
타우 병증을 치료하는 방법
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023053282A1
(ja)
|
2021-09-29 |
2023-04-06 |
中外製薬株式会社 |
がんの治療に用いるための細胞傷害誘導治療剤
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
JPWO2023058723A1
(ja)
|
2021-10-08 |
2023-04-13 |
|
|
CN118139648A
(zh)
|
2021-10-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的替代的PD1-IL7v免疫缀合物
|
AU2022362681A1
(en)
|
2021-10-14 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
TW202325742A
(zh)
|
2021-11-01 |
2023-07-01 |
瑞士商赫孚孟拉羅股份公司 |
使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
AU2022389969A1
(en)
|
2021-11-16 |
2024-05-02 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
AR127806A1
(es)
|
2021-12-01 |
2024-02-28 |
Kadmon Corp Llc |
Anticuerpos b7-h4 y proteínas de fusión de anticuerpo b7-h4 / il-15
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
TW202339797A
(zh)
|
2021-12-14 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
使用hla-a2mage-a4xcd3雙特異性抗體及4-1bb(cd137)促效劑治療癌症
|
CA3240565A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies and methods of use
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
AU2022423749A1
(en)
|
2021-12-20 |
2024-06-13 |
F. Hoffmann-La Roche Ag |
Agonistic ltbr antibodies and bispecific antibodies comprising them
|
AR128222A1
(es)
|
2022-01-07 |
2024-04-10 |
Johnson & Johnson Entpr Innovation Inc |
MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
TW202400636A
(zh)
|
2022-03-11 |
2024-01-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(一)
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
WO2023170295A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
TW202402790A
(zh)
|
2022-03-25 |
2024-01-16 |
英商梅迪繆思有限公司 |
減少呼吸系統感染之方法
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023192622A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
TW202408562A
(zh)
|
2022-04-13 |
2024-03-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024015993A1
(en)
|
2022-07-15 |
2024-01-18 |
Fibrogen, Inc. |
Modified anti-galectin-9 antibody and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240132622A1
(en)
|
2022-07-22 |
2024-04-25 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024040216A2
(en)
|
2022-08-19 |
2024-02-22 |
Fibrogen, Inc. |
Anti-ccr8 antibodies and uses thereof
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024069180A2
(en)
|
2022-09-28 |
2024-04-04 |
LiliumX Ltd. |
Multivalent proteins and screening methods
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024074649A1
(en)
|
2022-10-05 |
2024-04-11 |
Alcea Therapeutics, Inc. |
Notch4 antibodies, compositions, and methods for treating airway inflammation
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024079010A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and cd38 antibodies
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
WO2024079009A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and proteasome inhibitors
|
WO2024079310A1
(en)
|
2022-10-14 |
2024-04-18 |
Ebbil, Ltd. |
Sil-6r and ctgf binding proteins and methods of use thereof
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024115349A1
(en)
|
2022-11-29 |
2024-06-06 |
F. Hoffmann-La Roche Ag |
Improved cancer immunotherapy
|